Document:

Exhibit 4.1 

 

Form
of Note

 

NEITHER
THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR
THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.

 

SHUTTLE
PHARMACEUTICALS HOLDINGS, INC.

 

CONVERTIBLE
NOTE

 

	Issuance
    Date: ____________ __, 2021	Original
    Principal Amount: $_____________
	Note
    No. __	 

 

FOR
VALUE RECEIVED, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (“Shuttle Pharma” or the “Maker”),
hereby promises to pay to the order of _________________________ (the “Subscriber”), or registered assigns (together
with the Subscriber, the “Holder”), the amount set out above as the Original Principal Amount, as reduced pursuant
to the terms hereof pursuant to redemption, conversion or otherwise (the “Principal”), when due, whether upon the
Maturity Date (as defined below), acceleration, redemption or otherwise (in each case in accordance with the terms hereof) and to pay
interest (“Interest”) on any outstanding Principal at the applicable Interest Rate from the date set out above as
the Issuance Date (the “Issuance Date”) until the same becomes due and payable, upon the Maturity Date or acceleration,
conversion, redemption or otherwise (in each case in accordance with the terms hereof).

 

The
Original Principal Amount is _________________________ Dollars ($__________). For purposes hereof, the term “Outstanding Balance”
means the Original Principal Amount, as reduced or increased, as the case may be, pursuant to the terms hereof for conversion, breach
hereof or otherwise, plus any accrued but unpaid interest, collection and enforcements costs, and any other fees or charges incurred
under this Note provided that, in the event of an optional or mandatory conversion of the Note into
shares of Common Stock (as provided herein), all accrued interest on the Principal subject to such conversion shall be waived.

 

This
Note is being issued pursuant to the terms of a subscription agreement dated as of ____ __, 2021 between the Maker and the Subscriber
and exhibits thereto (collectively, the “Transaction Documents”). Unless otherwise defined herein, all capitalized
terms, when used in this Note, shall have the same meaning as they are defined in the Transaction Documents.

 

1. GENERAL
TERMS

 

(a) Payment
of Principal. Unless previously converted into shares of the common stock, $0.00001par value, of Shuttle Pharma or the common stock
of any successor in interest to the Maker (each the “Common Stock”) as contemplated hereby, this Note, together with
all accrued interest hereon at the Interest Rate, shall be due and payable on December 31, 2024 (the “Maturity Date”).
In the event that within 12 months of the Issuance Date, the Maker shall not have consummated an initial public offering of its Common
Stock and the listing or trading of its Common Stock on a “Qualified Securities Market”, as defined below (the “IPO”)
or other “Liquidity Event” (hereinafter defined), the Maker may elect either (a) up on thirty (30) days prior written
notice to the Holder, elect to prepay all of the principal amount of the Note and accrued interest hereon, subject to the Holder’s
right to convert the Note into Common Stock during such thirty (30) day period, or (b) if the Maker does not prepay the entire principal
amount of the Note or the remaining principal amount of the Note, this Note will automatically increase to 110% of the original or unpaid
portion of the outstanding principal amount.

 

    	 

     

    

 

(b) Interest.
Interest shall accrue from the Issuance Date on the Original Principal Amount or other outstanding Principal at an annual rate of six
percent (6%) (the “Interest Rate”) and all accrued interest shall be fully paid on the Maturity Date (or sooner as
provided herein) to the Holder or its assignee in whose name this Note is registered on the records of the Maker regarding registration
and transfers of Notes in cash. However, in the event of an optional or mandatory conversion of the Note into shares of Common Stock
(as provided herein), all accrued interest on the Principal subject to such conversion shall be waived.

 

2. EVENTS
OF DEFAULT.

 

Whenever
used herein, an “Event of Default” means the occurrence and continuation of any one of the following events, whatever
the reason, and whether it shall be voluntary or involuntary, or effected by operation of law or pursuant to any judgment, decree or
order of any court, or any order, rule or regulation of any administrative or governmental body:

 

(a) The
Maker’s failure to pay to the Holder any amount of Principal, Interest, or other amounts when and as due under this Note; or

 

(b) A
Conversion Failure as defined in Section 3(d)(ii); or

 

(c) A
material breach by Shuttle Pharma of any material representation, warranty or covenant contained in the Transaction Documents or a material
breach by Shuttle Pharma of any material representation, warranty or covenant contained in the Purchase Agreement, that, if capable of
cure, is not cured within 30 days from the date such breach has occurred; or

 

(d) The
Maker or any subsidiary of the Maker shall commence, or there shall be commenced against the Maker or any subsidiary of the Maker under
any applicable bankruptcy or insolvency laws as now or hereafter in effect or any successor thereto, or the Maker or any subsidiary of
the Maker commences any other proceeding under any reorganization, arrangement, adjustment of debt, relief of debtors, dissolution, insolvency
or liquidation or similar law of any jurisdiction whether now or hereafter in effect relating to the Maker or any subsidiary of the Maker
or there is commenced against the Maker or any subsidiary of the Maker any such bankruptcy, insolvency or other proceeding which remains
undismissed for a period of ninety-one (91) days; or the Maker or any subsidiary of the Maker is adjudicated insolvent or bankrupt; or
any order of relief or other order approving any such case or proceeding is entered; or the Maker or any subsidiary of the Maker suffers
any appointment of any custodian, private or court appointed receiver or the like for it or any substantial part of its property which
continues undischarged or unstayed for a period of ninety-one (91) days; or the Maker or any subsidiary of the Maker makes a general
assignment for the benefit of creditors; or the Maker or any subsidiary of the Maker shall fail to pay, or shall state that it is unable
to pay, or shall be unable to pay, its debts generally as they become due; or the Maker or any subsidiary of the Maker shall call a meeting
of its creditors with a view to arranging a composition, adjustment or restructuring of its debts; or the Maker or any subsidiary of
the Maker shall by any act or failure to act expressly indicate its consent to, approval of or acquiescence in any of the foregoing;
or any corporate or other action is taken by the Maker or any subsidiary of the Maker for the purpose of effecting any of the foregoing.

 

3. CONVERSION
OF NOTE. This Note shall be convertible into shares of Common Stock, on the terms and conditions set forth in this Section 3.

 

(a) Certain
Definitions. As used in this Note, the following capitalized terms shall have the meaning set forth below:

 

(i) “Alternative
Liquidity Event” shall mean any one of a Sale of Control, a SPAC Acquisition, or a Reverse Merger.

 

    	 

     

    

 

(ii)
“Alternative Liquidity Event Conversion Price” shall mean a conversion price that is equal to 50% of the
aggregate “Transaction Consideration” (as defined) divided by the total number of outstanding shares of common stock of
the acquiror resulting from a Sale of Control, the merger with a SPAC or the successor in interest “Pubco” (as
defined) in connection with a Reverse Merger.

 

(iii) “Common
Stock” shall mean, as applicable, the individual or collective reference to the Common stock, $0.00001 par value per share,
of the Maker or the common stock of any acquiror in a Sale of Control, SPAC or Pubco resulting from a Sale of Control, SPAC Acquisition
or Reverse Merger.

 

(iv) “Conversion
Shares” shall mean the aggregate number of shares of Common Stock of the Maker, the Acquiror in a Sale of Control the SPAC
or Pubco, as applicable (each an “Issuer”) that are issuable to the Holder in connection with any mandatory conversion
(set forth in Section 3(b)) or optional conversion (set forth in Section 3(c)) of this Note.

 

(v) “IPO”
shall mean an initial public offering of Common Stock of the Maker pursuant to a registration statement on Form S-1 that is declared
effective by the Securities and Exchange Commission.

 

(vi) “IPO
Conversion Price” shall mean a conversion price equal to 50% of the initial public offering price per share of the Common Stock
offered to the public in the IPO.

 

(vii) “Liquidity
Event” shall mean any one of an IPO, a Sale of Control, a SPAC Acquisition or a Reverse Merger.

 

(viii)
“Optional Conversion Price” shall mean a conversion price that is equal to the price per share determined by dividing
$50 million by the total number of outstanding shares of Common Stock of the Maker.

 

(ix) “Pre-Money
Valuation” shall mean the dollar value placed on the total number of outstanding shares of Common Stock and Preferred Stock
of the Company immediately prior to a Liquidity Event.

 

(x) “Preferred
Stock” means the Series A convertible preferred stock, par value $0.00001 per share, of the Company, of which there are 1,212.5
shares outstanding.

 

(xi) “Pubco”
means a fully-reporting public corporation under the Securities Exchange Act of 1934, as amended, that does not have any significant
business activities and is trading on Nasdaq or the OTCQX platform of the OTC Market.

 

(xii) “Qualified
Securities Market” shall mean any one of the Nasdaq Stock Exchange (including the Nasdaq Capital Market), the NYSE:Amex Exchange,
the New York Stock Exchange or the OTCQX platform of the OTC Markets.

 

(xiii) “Reverse
Merger” means a merger of the Maker with or the acquisition of the Maker by Pubco, as a result of which such transaction, the
stockholders of the Maker will own a substantial majority of the equity securities of Pubco.

 

(xiv)
“Sale of Control” shall mean a sale of all or substantially as of the capital stock or assets of the Company to any
unaffiliated third Person, whether through share sale, asset sale, merger, consolidation or like combination, as a result of which the
ability to control the board of directors of the Company shall pass to such third Person.

 

    	 

     

    

 

(xv) “SPAC”
means a special purpose acquisition corporation whose securities are listed on Nasdaq or the New York Stock Exchange.

 

(xvi) “SPAC
Acquisition” means a merger of the Maker with or the acquisition of the Maker by a SPAC or its subsidiary, as a result of which
such transaction, the stockholders of the Maker will own a majority of the equity securities of the SPAC.

 

(xvii) “Transaction
Consideration” shall mean the dollar value placed on the total consideration paid to the Company including, but not limited
to, (i) the value of the Transaction, including consideration whether in cash, stock or in-kind, received by and/or paid by the Company,
(ii) the total amount of indebtedness for borrowed funds, capitalized lease obligations and non-trade liabilities of the Company that
are either assumed by the acquirer, redeemed or otherwise satisfied in connection with the transaction, or which remain outstanding after
the transaction is consummated; (iii) the fair market value of any assets excluded from the transaction; (iv) the fair market value of
any ownership interests which are retained by the Company’s shareholders or which remain outstanding after the transaction is consummated;
and (v) the amount of any contingent payments, including, without limitation, earn-outs and future royalties payable in connection with
the transaction.

 

(b) Mandatory
Conversion. In the event that prior to the Maturity Date of this Note, the Maker shall consummate an IPO and its Common Stock shall
be approved for listing or trading on any Qualified Securities Market, the entire Outstanding Balance of this Note shall automatically,
and without any further consent or approval of the Holder, be converted into Common Stock of the Maker at the IPO Conversion Price. In
the event that prior to the Maturity Date, the Maker shall consummate an Alternative Liquidity Event, the Holder may elect at his or
its option to convert the outstanding and unpaid Outstanding Balance of this Note into Common Stock of the Maker at the Alternative Liquidity
Event Conversion Price. The IPO Conversion Price and the Alternative Liquidity Event Conversion Price (either, the “Mandatory
Conversion Price”) shall be subject to adjustment, as provided for in Section 3(f) below.

 

(c) Optional
Conversion. At any time, at the Holder’s option, such Holder may convert the outstanding and unpaid Outstanding Balance of
this Note into fully paid and nonassessable shares of Common Stock in accordance with this Section 3(c), at the Optional Conversion
Price, subject to adjustment as provided in Section 3(f) below. If the issuance would result in the issuance of a fraction of
a share of Common Stock, Shuttle Pharma shall round such fraction of a share of Common Stock up to the nearest whole share. Shuttle Pharma
shall pay any and all transfer agent fees, legal fees, costs and any other fees or costs that may be incurred or charged in connection
with the issuance and legend removal of shares of Common Stock to the Holder arising out of or relating to the conversion of this Note
up to a maximum of five thousand dollars ($5,000).

 

(d) Mechanics
of Conversion.

 

(i) Optional
Conversion. To convert the Note pursuant to an optional conversion into shares of Common Stock on any date (a “Conversion
Date”), the Holder shall (A) transmit by email, facsimile (or otherwise deliver), for receipt on or prior to 11:59 p.m., New
York, NY Time, a copy of an executed notice of conversion in the form attached hereto as Exhibit A (the “Conversion Notice”)
to Shuttle Pharma. On or before the tenth (10th) Business Day following the date of receipt of a Conversion Notice (the “Share
Delivery Date”), Shuttle Pharma shall (A) if legends are not required to be placed on certificates of Common Stock pursuant
to the then existing provisions of Rule 144 of the Securities Act of 1933 (“Rule 144”) and provided that the Transfer
Agent is participating in the Depository Trust Company (“DTC”) Fast Automated Securities Transfer Program, credit
such aggregate number of shares of Common Stock to which the Holder shall be entitled to the Holder’s or its designee’s balance
account with DTC through its Deposit Withdrawal Agent Commission system or (B) if the Transfer Agent is not participating in the DTC
Fast Automated Securities Transfer Program, issue and deliver to the address as specified in the Conversion Notice, a certificate, registered
in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder shall be entitled which certificates
shall not bear any restrictive legends unless required pursuant the Rule 144. The Person or Persons entitled to receive the shares of
Common Stock issuable upon a conversion of this Note shall be treated for all purposes as the record holder or holders of such shares
of Common Stock upon the transmission of a Conversion Notice.

 

    	 

     

    

 

(ii) Issuer’s
Failure to Timely Convert. If within ten (10) business days after a Liquidity Event or (in the case of an optional conversion) Shuttle
Pharma receipt of the facsimile or email copy of a Conversion Notice together with documentation satisfactory to the Transfer Agent that
the Conversion Shares are eligible for such electronic issuance, the Issuer shall fail to issue and deliver to Holder via “DWAC/FAST”
electronic transfer (assuming that such shares are “DWAC/FAST” eligible) the number of Conversion Shares to which the Holder
is entitled upon such holder’s conversion of any Conversion Shares (a “Conversion Failure”), the Outstanding
Balance of the Note shall increase by 0.05% per day until such time as the Issuer of the Conversion Shares issues and delivers a certificate
to the Holder or credit the Holder’s balance account with DTC for the number of Conversion Shares to which the Holder is entitled
upon such mandatory or optional conversion. The Issuer of the Conversion Shares will not be subject to any penalties once its transfer
agent processes the shares to the DWAC system. If the issuer fails to deliver shares in accordance with the timeframe stated in this
Section, resulting in a Conversion Failure, the Holder, at any time prior to selling all of those Conversion Shares, may rescind any
portion, in whole or in part, of that particular conversion attributable to the unsold shares and have the rescinded conversion amount
returned to the Outstanding Balance with the rescinded Conversion Shares returned to the applicable Issuer.

 

(iii) Book-Entry.
Notwithstanding anything to the contrary set forth herein, in connection with any optional or mandatory conversion of this Note in accordance
with the terms hereof, the Holder shall not be required to physically surrender this Note to Shuttle Pharma unless and until such time
as the Holder has converted his or her shares in full. Upon a partial or full conversion, Holder shall receive either (i) one or more
stock certificates, or a book entry account statement, evidencing the Conversion Shares (in the event Shuttle Pharma’s Common Stock
is not yet DTC eligible) or (ii) physical evidence from the Issuer’s transfer agent that the Holder’s balance account with
DTC showing that the Conversion Shares have been credited for the number of Conversion Shares to which the Holder is entitled upon such
mandatory or optional conversion. The Holder and the Issuer shall maintain records showing the Outstanding Balance converted and the
dates of such conversions or shall use such other method reasonably satisfactory to the Holder and Issuer, so as not to require physical
surrender of this Note upon conversion, unless so requested by Shuttle Pharma.

 

(e) Limitations
on Conversions or Trading.

 

If
at any time after the Closing, the Holder shall or would receive Conversion Shares or shall purchase additional shares of Common Stock
of an Issuer, so that the Holder would, together with other shares of Common Stock held by it or its Affiliates, own or beneficially
own by virtue of such action or receipt of additional shares of Common Stock a number of shares exceeding 9.99% of the number of shares
of Common Stock outstanding on such date (the “Maximum Percentage”), the Issuer shall not be obligated and shall not
issue to the Holder Conversion Shares which would exceed the Maximum Percentage, but only until such time as the Maximum Percentage would
no longer be exceeded by any such receipt of shares of Common Stock by the Holder. Upon delivery of a written notice to the applicable
Issuer the Holder may from time to time increase (with such increase not effective until the sixty-first (61st) day after delivery of
such notice) or decrease the Maximum Percentage to any other percentage not in excess of 9.99% as specified in such notice; provided
that (i) any such increase in the Maximum Percentage will not be effective until the sixty-first (61st) day after such notice is delivered
to Shuttle Pharma and (ii) any such increase or decrease will apply only to the Holder and its Affiliates. The provisions of this paragraph
shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 3(e) to the extent
necessary to correct this paragraph (or any portion of this paragraph) which may be defective or inconsistent with the intended beneficial
ownership limitation contained in this Section 3(e) or to make changes or supplements necessary or desirable to properly give
effect to such limitation. The limitation contained in this paragraph may not be waived and shall apply to a successor holder of the
Note.

 

(f) Adjustment
of Conversion Price. In the event that a Liquidity Event prior to the December 31, 2024 Maturity Date of this Note, the Maker shall
raise additional capital through a private placement of Common Stock or other securities that are convertible or exercisable for Common
Stock, in either case, at a price less than the Optional Conversion Price, then and in such event the Conversion Price of the Notes shall
be adjusted to reflect such lower amount.

 

    	 

     

    

 

(g) Other
Provisions.

 

(i) Share
Reservation. Shuttle Pharma shall at all times reserve and keep available out of its authorized Common Stock a number of shares equal
to at least the full number of shares of Common Stock issuable upon conversion of all outstanding amounts under this Note.

 

(ii)
Prepayment. This Note may not be prepaid by Shuttle Pharma until March 31, 2022. Thereafter, the Note may either be prepaid by
the Company in whole or in part without penalty, fees or premium upon not less than twenty (20) business days prior written notice to
the Holder (the “Prepayment Notice”) which shall set forth the date on which the Note shall be prepaid (the “Prepayment
Date”), subject to the Holder’s right to convert all or any portion of this Note into Conversion Shares at the Optional
Conversion Price prior to the Prepayment Date.

 

(iii) All
calculations under this Section 3 shall be rounded up to the nearest whole share.

 

(iv) Nothing
herein shall limit a Holder’s right to pursue actual damages or declare an Event of Default pursuant to Section 2 herein for Shuttle
Pharma’s failure to deliver certificates or credit entries representing shares of Common Stock upon conversion within the period
specified herein and such Holder shall have the right to pursue all remedies available to it at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief, in each case without the need to post a bond or provide other security. The
exercise of any such rights shall not prohibit the Holder from seeking to enforce damages pursuant to any other Section hereof or under
applicable law.

 

(v) The
Maker shall use its best efforts to assist the Holder to obtain a legal opinion for the removal of any restrict legend in connection
with any shares converted from this Note.

 

(vi) This
Note is one of the Convertible Notes issued on or about the date of this Note by the Maker in an aggregate principal amount of up to
$2,000,000, (the “Notes”). Each of the Notes shall rank equally without preference or priority of any kind over one
another, and all payments and recoveries under the Notes payable on account of principal and interest on the Notes shall be paid and
applied ratably and proportionately on the balance of all outstanding Notes on the basis of their original principal amount.

 

4. REISSUANCE
OF THIS NOTE.

 

Upon
receipt by the Maker of evidence reasonably satisfactory to the Maker of the loss, theft, destruction or mutilation of this Note, and,
in the case of loss, theft or destruction, of any indemnification undertaking by the Holder to the Maker in customary form and, in the
case of mutilation, upon surrender and cancellation of this Note, the Maker shall execute and deliver to the Holder a new Note representing
the outstanding Principal.

 

5.
NOTICES. Any notices, consents, waivers or other communications required or permitted to be given under the terms shall be handled
according to the Notice clause in the Subscription Agreement.

 

The
addresses for such communications shall be:

 

If
to the Maker:

Dr.
Anatoly Dritschilo, CEO

Shuttle
Pharmaceuticals Holdings, Inc.

One
Research Court, Suite 450

Rockville,
MD 20850

Email:
[ ]@shuttlepharma.com

 

If
to the Holder:

 

    	 

     

    

 

6.
APPLICABLE LAW AND VENUE. This Note shall be governed by and construed in accordance with the laws of the State of New York, without
giving effect to conflicts of laws thereof. Any action brought by either party against the other concerning the transactions
contemplated by this Agreement shall be brought only in the state courts of New York or in the federal courts located in New York
County, in the State of New York. Both parties and the individuals signing this Agreement agree to submit to the jurisdiction of
such courts.

 

7. WAIVER.
Any waiver by the Holder of a breach of any provision of this Note shall not operate as or be construed to be a waiver of any other breach
of such provision or of any breach of any other provision of this Note. The failure of the Holder to insist upon strict adherence to
any term of this Note on one or more occasions shall not be considered a waiver or deprive that party of the right thereafter to insist
upon strict adherence to that term or any other term of this Note. Any waiver must be in writing.

 

8. MISCELLANEOUS

 

(a) Lawful
Money; Costs of Collection. All amounts payable hereunder are payable in lawful money of the United States. Shuttle Pharma agrees
to pay all costs of collection when incurred, including reasonable attorneys’ fees and costs, whether or not a suit or action is
instituted to enforce this Note, including but not limited to court costs, appraisal fees, the cost of searching records, obtaining title
reports and title insurance and trustee’s fees, to the extent permitted by applicable law.

 

(b) No
Offset; Holder in Due Course. All payments under this Note made by or on behalf of Shuttle Pharma shall be made without setoff or
counterclaim and free and clear of, and without deduction or withholding for or on account of, any federal, state, or local taxes. Shuttle
Pharma waives any right of offset it now has or may hereafter have against Agent or Holder and its successors and assigns as to this
Note (but retains any such rights as to any other prior or future transaction between these parties), and agrees to make the payments
called for hereunder in accordance with the terms hereof. The holder hereof and all successors thereof shall have all the rights of a
holder in due course as provided in the Delaware Uniform Commercial Code and other laws of the State of Delaware.

 

(c) Waivers.
Shuttle Pharma and any endorsers, guarantors or sureties hereof severally waive presentment and demand for payment, notice of intent
to accelerate maturity, protest or notice of protest or non-payment, bringing of suit and diligence in taking any action to collect
any sums owing hereunder or in proceeding against any of the rights and properties securing payment hereunder; expressly agree that
this Note, or any payment hereunder, may be extended from time to time; and consent to the acceptance of further security or the
release of any security for this Note, all without in any way affecting the liability of Shuttle Pharma and any endorsers or
guarantors hereof. No extension of time for the payment of this Note, or any installment hereof, made by agreement by the holder
hereof with any person now or hereafter liable for the payment of this Note, shall affect the original liability under this Note of
Shuttle Pharma, even if Shuttle Pharma (or any entity comprising Shuttle Pharma) is not a party to such agreement.

 

(d) Usury
Protection. The parties hereto intend to conform strictly to the applicable usury laws. In no event, regardless of any provisions
contained therein or in any other document executed or delivered in connection herewith, shall the holder hereof ever be deemed to have
contracted for or be entitled to receive, collect or apply as interest on this Note, any amount in excess of the maximum amount permitted
by applicable law (the “Maximum Rate”). In no event, whether by reason of demand for payment, prepayment, acceleration
of the maturity hereof or otherwise, shall the interest contracted for, charged or received by the holder hereunder or otherwise exceed
the Maximum Rate. If for any circumstance whatsoever interest would otherwise be payable to the holder in excess of the maximum lawful
amount, the interest payable to the holder shall be reduced automatically to the Maximum Rate and any payment received in excess of such
amount shall be applied to the outstanding principal balance of the Note.

 

(e) Entire
Agreement. This Note, the other Transaction Documents, and all other documents and instruments contemplated hereby and thereby together
constitute the entire agreement between and among the parties pertaining to the subject matter hereof. No supplement, modification or
amendment of this Note shall be binding unless executed in writing by the parties. No waiver shall be binding unless executed in writing
by the party making the waiver. No provision of this Note shall be interpreted for or against the drafting party.

 

    	 

     

    

 

(f) Commercial
Purpose. Shuttle Pharma agrees that no funds advanced under this Note shall be used for personal, family or household purposes, and
that all funds advanced hereunder shall be used solely for business, commercial, investment or other similar purposes.

 

(g) Successors
and Assigns. All the terms and provisions of this Note shall be binding upon and inure to the benefit of the parties to this Note
and their respective successors and assigns.

 

(h) Assignment.
Shuttle Pharma may not, voluntarily or involuntarily, directly or indirectly, by operation of law or otherwise, sell, transfer, assign,
hypothecate, pledge or in any way alienate this Note or any right or interest in this Note (each a “Transfer”) without
Holder’s prior written consent, which Holder may withhold in its sole and absolute discretion. Any consent by Holder to any Transfer
shall not constitute consent to any other Transfer. Holder may freely Transfer its interest, rights, or title in or to this Note or the
other Transaction Documents in Holder’s sole and absolute discretion.

 

(i) Construction.
Whenever used in this Note, the terms “including,” “include,” “includes” and the like are not
intended as terms of limitation, and, hence, shall be deemed to be followed by “without limitation.”

 

(j) Severability.
If any provision of this Note, as applied to any party or to any circumstance, shall be found by a court of competent jurisdiction to
be void, invalid or unenforceable, the same shall in no way affect any other provision of this Note, the application of any such provision
in any other circumstance, or the validity or enforceability of this Note, and any provision which is found to be void, invalid or unenforceable
shall be curtailed and limited only to the extent necessary to bring such provision within the requirements of the law.

 

(k) Survival
of Terms. The terms and provisions of this Note shall survive the Maturity Date until full payment of all amounts due hereunder.

 

(l) Preferential
Payment. If at any time any payment made pursuant to this Note is deemed to have been a voidable preference, fraudulent conveyance
or other similar conveyance or preferential payment under any bankruptcy, insolvency or other debtor relief or similar law, then the
obligation to make such payment shall survive any cancellation or satisfaction of this Note or return of this Note to Shuttle Pharma
and shall not be discharged or satisfied with any such payment or cancellation. Such payment shall instead remain a valid and binding
obligation enforceable in accordance with the terms of this Note and shall be immediately due and payable.

 

(m) Relief
From Stay. As an additional inducement to and material consideration for Holder agreeing to execute this this Note and the other
Transaction Documents, Shuttle Pharma agrees that in the event a Bankruptcy or Judicial Action (as hereinafter defined in this Section
8(n)) is commenced which subjects Holder to any stay in the exercise of Holder’s rights and remedies under this Note or the
other Transaction Documents, including, but not limited to, the automatic stay imposed by Section 362 of the United States Bankruptcy
Code (individually and collectively, “Stay”), then Shuttle Pharma irrevocably consents and agrees that such Stay shall
automatically be lifted and released against Holder, and Holder shall thereafter be entitled to exercise all of its rights and remedies
against Shuttle Pharma that is or could be subject any Stay under this Note or the other Transaction Documents. Nothing contained herein
shall limit or prevent Holder from exercising all of its rights and remedies against Shuttle Pharma that is not the subject any Stay
under this Note or the other Transaction Documents. Shuttle Pharma acknowledges that it is knowingly, voluntarily, and intentionally
waiving its rights to any Stay and agrees that the benefits provided to Shuttle Pharma under the terms of this Note are valuable consideration
for such waiver. As used in this Section 8(n), the term “Bankruptcy or Judicial Action” shall mean any voluntary
or involuntary case filed by or against a Shuttle Pharma under the United States Bankruptcy Code, or any voluntary or involuntary petition
in composition, readjustment, liquidation, or dissolution, or any state and federal bankruptcy law action filed by or against a Shuttle
Pharma, any action where a Shuttle Pharma is adjudicated as bankrupt or insolvent, any action for dissolution of a Shuttle Pharma, or
any action in furtherance of any of the foregoing, or any other action, case, or proceeding that has the effect of staying (or in which
a stay is being obtained against) the enforcement by Holder of its rights and remedies under the this Note or the other Transaction Documents.

 

    	 

     

    

 

Except
to enforce the terms of the Transaction Documents, Shuttle Pharma shall not take any action and shall not fail to take any action which
such action or omission will or might tend to interfere with, delay, enjoin or otherwise prohibit the commencement, continuation or completion
of efforts by Holder to enforce its remedies under this Note or the other Transaction Documents, or applicable law. Without limiting
the generality of the foregoing and except to enforce the terms of the Transaction Documents, each Shuttle Pharma waives its, his, or
her rights, if any, to seek or obtain a stay, injunction or other form of order prohibiting in any way any act necessary or appropriate
for the commencement or completion of Holder’s enforcement of its remedies under the this Note or the other Transaction Documents,
or applicable law (without limiting the generality of the foregoing, such waiver extends to such rights which may exist under any statute
or rule relating to bankruptcy cases, including, without limitation, 11 U.S.C. § 105, 11 U.S.C. § 301, 11 U.S.C. § 302,
11 U.S.C. § 303, 11 U.S.C. § 304, 11 U.S.C. § 362, 11 U.S.C. § 348, 11 U.S.C. § 706, 28 U.S.C. § 157, 28
U.S.C. § 158, Federal Rule of bankruptcy Procedure (“FRBP”) 3007, FRBP 3008, FRBP 3012, FRBP 8005, FRBP 9023, FRBP 9024,
or FRBP 9029).

 

9. AMENDMENT
AND WAIVER OF RIGHTS. This Note may be amended and the observance of any term hereof may be waived (either generally or in a particular
instance either retroactively or prospectively) only by a written instrument executed by the Maker and the Holder.

 

10. WAIVER
OF RIGHT TO TRIAL BY JURY.

 

EACH
PARTY TO THIS NOTE HEREBY EXPRESSLY WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION (1) ARISING UNDER
THIS NOTE, THE OTHER TRANSACTION DOCUMENTS, OR ANY OTHER INSTRUMENT, DOCUMENT, OR AGREEMENT EXECUTED OR DELIVERED IN CONNECTION THEREWITH,
OR (2) IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO OR ANY OF THEM WITH RESPECT TO THIS NOTE
OR ANY OTHER INSTRUMENT, DOCUMENT, OR AGREEMENT EXECUTED OR DELIVERED IN CONNECTION HEREWITH, OR THE TRANSACTIONS RELATED HERETO OR THERETO,
IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER SOUNDING IN CONTRACT OR TORT OR OTHERWISE; AND EACH PARTY HEREBY
AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY. THE PARTIES
HERETO HEREBY AGREE THAT THE PROVISIONS CONTAINED HEREIN HAVE BEEN FAIRLY NEGOTIATED ON AN ARM’S-LENGTH BASIS, WITH BOTH SIDES
AGREEING TO THE SAME KNOWINGLY AND BEING AFFORDED THE OPPORTUNITY TO HAVE THEIR RESPECTIVE LEGAL COUNSEL CONSENT TO THE MATTERS CONTAINED
HEREIN. ANY PARTY TO THIS NOTE MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT
OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY AND THE AGREEMENTS CONTAINED HEREIN REGARDING THE APPLICATION OF
JUDICIAL REFERENCE IN THE EVENT OF THE INVALIDITY OF SUCH JURY TRIAL WAIVER.

 

IN
WITNESS WHEREOF, each of the Maker has caused this Note to be duly executed by a duly authorized officer as of the date set forth above.

 

	 	Shuttle
    Pharmaceuticals Holdings, Inc.
	 	 
	 	By:	
	 	Name:	Dr.
    Anatoly Dritschilo
	 	Title:	Chief
    Executive Officer

 

Note
No. [   ]

 

    	 

     

    

 

EXHIBIT
A

 

NOTICE
OF CONVERSION

 

Shuttle
Pharmaceuticals Holdings, Inc.

One
Research Court, Suite 450

Rockville,
MD 20850

Email:
[      ]@shuttlepharma.com

 

The
undersigned hereby elects to convert $[     ] of the $[     ] Convertible Note (Note No. [     ]) issued to [                    ] on [     ], 2021 into Shares of Common
Stock of Shuttle Pharmaceuticals Holdings, Inc. according to the conditions set forth in such Note as of the date written below.

 

If
the number of shares to be delivered represents more than 4.99% of the common stock outstanding, this conversion notice shall immediately
automatically extinguish and Holder must be immediately notified.

 

	Date
    of Conversion:	 
	Optional
    Conversion Amount:	 
	Conversion
    Price:	 
	Shares
    to be Delivered:	 
	Shares
    delivered in name of:	 

 

	 	HOLDER
	 	 
	 	[      ]
	 	 	 
	 	By:	
	 	 	     
	 	Title:Exhibit
10.1

 

FINAL

 

SUBSCRIPTION
AGREEMENT

 

Shuttle
Pharmaceuticals Holdings, Inc.

One
Research Court, Suite 450

Rockville,
MD 20850

 

This
Subscription Agreement (this “Agreement”) has been executed by the subscriber set forth on the signature page
hereof (the “Subscriber”) in connection with the private placement offering (the “Offering”)
of a minimum of $2,500,000 (the “Minimum Offering”) and a maximum of $10,000,000 (the “Maximum
Offering”) of Units of securities (the “Units”), plus up to an additional $1,500,000 of Units
to cover over-subscriptions, issued by Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”),
at a purchase price of $1,000 per Unit (the “Purchase Price”). Each Unit consists of (i) one share of the Company’s
Series A Convertible Preferred Stock, par value $0.00001 per share, with a Stated Value of $1,000 per share (the “Series A Preferred
Stock”), and (ii) a warrant, substantially in the form of Exhibit A hereto (the “Warrant”),
representing the right to purchase a number of shares of the Company’s common stock, par value $0.00001 per share (“Common
Stock”), equal to the number of shares into which a share of Series A Preferred Stock will be converted, with such Warrant
to be issued upon the earlier of (a) the closing of the sale of shares of Common Stock to the public at a price per share of at least
$13.88 (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization
with respect to the Common Stock), in a firm commitment underwritten public offering pursuant to an effective registration statement
under the Securities Act, resulting in gross proceeds (before underwriters’ discount, commissions and expenses) to the Company
of at least the difference between $15,000,000 and the gross proceeds of this Offering (a “Qualified IPO”),
or (b) listing (a “Listing”) of the Common Stock on the New York Stock Exchange, NYSE American, Nasdaq Global
Select Market, Nasdaq Global Market or Nasdaq Capital Market (a “Qualified Exchange”). Such Warrant shall be
exercisable for a period of three (3) years from the date of issuance at the per share price of the Company’s initial public offering
(“IPO”) or, if a Qualified IPO has not yet occurred, at $20.82/per share. Each share of Series A Preferred Stock is
convertible into shares of Common Stock (the “Conversion Shares”) at a conversion price and on the other terms
set forth in the Certificate of Designations (as defined below). The certificate of designations setting forth the resolution of the
Board of Directors of the Company establishing the Series A Preferred Stock and stating the number of authorized shares thereof and the
voting powers, designations, preferences, limitations, restrictions and relative rights of the Series A Preferred Stock (the “Certificate
of Designations”) shall be substantially in the form of Exhibit B hereto.

 

The
minimum subscription is $50,000 (50 Units). The Company may accept subscriptions for less than $50,000 in its sole discretion.

 

The
Units being subscribed for pursuant to this Agreement have not been registered under the Securities Act of 1933, as amended (the “Securities
Act”). The Offering is being made on a reasonable best efforts basis to “accredited investors,” as defined
in Regulation D under the Securities Act in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the
Securities Act and Rule 506 of Regulation D. The Subscriber acknowledges receipt of a copy of the Registration Rights Agreement, substantially
in the form of Exhibit C hereto (the “Registration Rights Agreement”).

 

Each
closing of the Offering (a “Closing,” and the date on which such Closing occurs hereinafter referred to as
the “Closing Date”) shall take place at the offices of CKR Law LLP, at 1330 Avenue of the Americas, New York,
New York 10019 (or such other place as is mutually agreed to by the Company and the Placement Agent (as defined below)).

 

    	 

     

    

 

The
initial Closing will not occur unless:

 

		a.	funds
                                            deposited in escrow as described in Section 2(b) below equal at least the Minimum Offering,
                                            and corresponding documentation with respect to such amounts has been delivered by the Subscriber
                                            and other “Subscribers” under Subscription Agreements of like tenor with this
                                            Agreement (collectively, the “Subscribers”) as described in Section
                                            2(a) below; and

 

		b.	the
                                            other conditions set forth in Sections 7 and 8 shall have been satisfied.

 

Thereafter,
the Company may conduct one or more additional Closings for the sale of the Units up to the Maximum Offering amount until the termination
of the Offering, and then for the sale of Units upon any exercise of the Option. Unless terminated earlier by the Company, the Offering
shall continue until September 15, 2018, which date may be extended up to an additional sixty days by the Company, without notice to
any Subscriber, past, current or prospective.

 

Any
written disclosure schedules or other written information documents delivered to the Subscriber prior to Subscriber’s execution
of this Agreement, and any such document delivered to the Subscriber after Subscriber’s execution of this Agreement and prior to
the Closing of the Subscriber’s subscription hereunder, are collectively referred to as the “Disclosure Materials.”

 

“Business
Day” means a day, other than a Saturday or Sunday, on which banks in New York City are open for the general transaction
of business.

 

	1.	Subscription.
                                            The undersigned Subscriber hereby subscribes to purchase the number of Units set forth
                                            on the Omnibus Signature Page attached hereto, for the aggregate Purchase Price as set forth
                                            on such Omnibus Signature Page, subject to the terms and conditions of this Agreement and
                                            on the basis of the representations, warranties, covenants and agreements contained herein.

 

	2.	Subscription
                                            Procedure. To complete a subscription for the Units, the Subscriber must fully comply
                                            with the subscription procedure provided in this Section on or before the Closing Date for
                                            Subscriber’s Units.

 

		a.	Subscription
                                            Documents. On or before the Closing Date, the Subscriber shall review, complete and execute
                                            the Omnibus Signature Page to this Agreement, the Investor Profile, Anti-Money Laundering
                                            Form and Accredited Investor Certification, each attached hereto following the Omnibus Signature
                                            Page (collectively, the “Subscription Documents”), and deliver
                                            the Subscription Documents to the Company’s attorneys, CKR Law LLP (“CKR”),
                                            at the address set forth under the caption “How to subscribe for Units in the private
                                            offering of Shuttle Pharmaceuticals Holdings, Inc.” below. Executed documents may
                                            be delivered to CKR by facsimile or electronic mail (e-mail), if the Subscriber delivers
                                            the original copies of the documents to CKR as soon as practicable thereafter.

 

		b.	Purchase
                                            Price. Simultaneously with the delivery of the Subscription Documents to CKR as
                                            provided herein, and in any event on or prior to the Closing Date, the Subscriber shall deliver
                                            to CKR, in its capacity as escrow agent (the “Escrow Agent”), under
                                            an escrow agreement among the Company, the Placement Agents (as defined below and the Escrow
                                            Agent (the “Escrow Agreement”), the full Purchase Price by certified
                                            or other bank check or by wire transfer of immediately available funds, pursuant to the instructions
                                            set forth under the caption “How to subscribe for Units in the private offering
                                            of Shuttle Pharmaceuticals Holdings, Inc.” below. Such funds will be held for the
                                            Subscriber’s benefit and will be returned promptly, without interest or offset, if
                                            this Subscription Agreement is not accepted by the Company or the Offering is terminated
                                            pursuant to its terms by the Company prior to the Closing.

 

    	2

     

    

 

		c.	Company
                                            Discretion. The Subscriber understands and agrees that the Company in its sole discretion
                                            reserves the right to accept or reject this or any other subscription for Units, in whole
                                            or in part, notwithstanding prior receipt by the Subscriber of notice of acceptance of this
                                            subscription. The Company shall have no obligation hereunder until the Company shall execute
                                            and deliver to the Subscriber an executed copy of this Agreement. If this subscription is
                                            rejected in whole, or if the Offering is terminated, all funds received from the Subscriber
                                            will be returned without interest or offset, and this Agreement shall thereafter be of no
                                            further force or effect. If this subscription is rejected in part, the funds for the rejected
                                            portion of this subscription will be returned without interest or offset, and this Agreement
                                            will continue in full force and effect to the extent this subscription was accepted.

 

	3.	Placement
                                            Agent. The Company intends to engage a broker-dealer licensed with FINRA as placement
                                            agent (the “Placement Agent”) for the Offering on a reasonable
                                            best efforts basis. The Company anticipates that the Placement Agent and its sub-agents will
                                            be paid at each Closing from the proceeds in the Escrow Account, a cash commission of 8%
                                            of the gross Purchase Price paid by Subscribers in the Offering and will receive warrants
                                            to purchase a number of shares of Common Stock equal to 8% of the number of Conversion Shares
                                            initially issuable upon conversion of the shares of Series A Preferred Stock contained in
                                            the Units sold in the Offering to investors, with a term of three (3) years from the relevant
                                            Closing Date, and at a per share exercise price equal to that of the Warrants issued to the
                                            Subscribers herein (the “Placement Agent Warrants”). Any sub-agent
                                            of the Placement Agent that introduces investors to the Offering will be entitled to share
                                            in the cash fees and Placement Agent Warrants attributable to those investors as described
                                            above, pursuant to the terms of an executed sub-agent agreement). The Company will also pay
                                            certain expenses of the Placement Agent.

 

	4.	Representations
                                            and Warranties of the Company. The Company hereby represents and warrants to the Subscriber,
                                            as of the date hereof and on each Closing Date after giving effect to the Merger (unless
                                            otherwise specified), the following:

 

		a.	Organization
                                            and Qualification. The Company and each of its subsidiaries is a corporation or other
                                            business entity duly organized, validly existing and in good standing under the laws of the
                                            jurisdiction of its formation, and has the requisite corporate power to own its properties
                                            and to carry on its business as now being conducted. The Company and each of its subsidiaries
                                            is duly qualified as a foreign corporation to do business and is in good standing in every
                                            jurisdiction in which the nature of the business conducted by it makes such qualification
                                            necessary, except to the extent that the failure to be so qualified or be in good standing
                                            would not have a material adverse effect on the assets, business, financial condition, results
                                            of operations or future prospects of the Company and its subsidiaries taken as a whole (a
                                            “Material Adverse Effect”).

 

    	3

     

    

 

		b.	Authorization,
                                            Enforcement, Compliance with Other Instruments. (i) The Company has the requisite corporate
                                            power and authority to enter into and perform its obligations under this Agreement, the Series
                                            A Preferred Stock, the Warrants, the Registration Rights Agreement, the Escrow Agreement
                                            and each of the other agreements and documents that are exhibits hereto or thereto or are
                                            contemplated hereby or thereby or necessary or desirable to effect the transactions contemplated
                                            hereby or thereby (the “Transaction Documents”) and to issue the
                                            shares of Series A Preferred Stock contained in the Units (the “Shares”)
                                            and the Warrants, and Conversion Shares and the shares of Common Stock issuable upon exercise
                                            of the Warrants (the “Warrant Shares”), in accordance with the
                                            terms hereof and thereof, (ii) the execution and delivery by the Company of each of the Transaction
                                            Documents and the consummation by it of the transactions contemplated hereby and thereby,
                                            including, without limitation, the issuance of the Shares, the Conversion Shares, the Warrants
                                            and the Warrant Shares, have been, or will be at the time of execution of such Transaction
                                            Document, duly authorized by the Company’s Board of Directors, and no further consent
                                            or authorization is, or will be at the time of execution of such Transaction Document, required
                                            by the Company, its respective Board of Directors or its stockholders, (iii) each of the
                                            Transaction Documents will be duly executed and delivered by the Company, (iv) the Transaction
                                            Documents when executed and delivered by the Company and each other party thereto will constitute
                                            the valid and binding obligations of the Company enforceable against the Company in accordance
                                            with their terms, except as such enforceability may be limited by general principles of equity
                                            or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar
                                            laws relating to, or affecting generally, the enforcement of creditors’ rights and
                                            remedies.

 

		c.	Capitalization.
                                            The authorized capital stock of the Company consists of 100,000,000 shares of Common Stock
                                            and 20,000,000 shares of preferred stock, par value of $0.00001 per share (the “Preferred
                                            Stock”). As of the date hereof, the Company has 18,000,000 shares of Common Stock
                                            and no shares of Preferred Stock issued and outstanding. All of the outstanding shares of
                                            Common Stock of the stock of each of the Company’s subsidiaries have been duly authorized,
                                            validly issued and are fully paid and nonassessable. No shares of capital stock of the Company
                                            or any of its subsidiaries will be subject to preemptive rights or any other similar rights
                                            or any liens or encumbrances suffered or permitted by the Company; (ii) there will be no
                                            outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any
                                            character whatsoever relating to, or securities or rights convertible into, any shares of
                                            capital stock of the Company or any of its subsidiaries, or contracts, commitments, understandings
                                            or arrangements by which the Company or any of its subsidiaries is or may become bound to
                                            issue additional shares of capital stock of the Company or any of its subsidiaries, (iii)
                                            there will be no outstanding debt securities of the Company or any of its subsidiaries other
                                            than indebtedness as set forth in the Company’s audited financial statements (“Financial
                                            Statements”), (iv) other than pursuant to the Registration Rights Agreement
                                            or as set forth in Financial Statements, there will be no agreements or arrangements under
                                            which the Company or any of its subsidiaries is obligated to register the sale of any of
                                            their securities under the Securities Act, (v) except as provided in this Agreement, there
                                            will be no securities or instruments of the Company or any of its subsidiaries containing
                                            anti-dilution or similar provisions, including the right to adjust the exercise, exchange
                                            or reset price under such securities, that will be triggered by the issuance of the Units
                                            as described in this Agreement; and (vi) no co-sale right, right of first refusal or other
                                            similar right will exist with respect to the Units (or will exist with respect to the Conversion
                                            Shares or the Warrant Shares) or the issuance and sale thereof. Upon request, the Company
                                            will make available to the Subscriber true and correct copies of the Company’s Certificate
                                            of Incorporation, and as in effect on the date hereof (the “Certificate of Incorporation”),
                                            and the Company’s By-laws, as in effect on the date hereof (the “By-laws”),
                                            and the terms of all securities exercisable for Common Stock and the material rights of the
                                            holders thereof in respect thereto other than stock options issued to officers, directors,
                                            employees and consultants.

 

    	4

     

    

 

		d.	Issuance
                                            of Securities. The Shares and the Warrants are duly authorized and, upon issuance in
                                            accordance with the terms hereof, shall be duly issued, fully paid and nonassessable, and
                                            are free and clear of all taxes, liens and charges with respect to the issue thereof. Upon
                                            issuance of the Conversion Shares upon conversion of the Shares, in accordance with the terms
                                            of the Certificate of Designations, the Conversion Shares will be duly issued, fully paid
                                            and nonassessable, and will be free from all taxes, liens and charges with respect to the
                                            issue thereof. Upon issuance of the Warrant Shares upon exercise of the Warrants, against
                                            payment therefor and in accordance with the terms of the Warrants, the Warrant Shares will
                                            be duly issued, fully paid and nonassessable, and will be free from all taxes, liens and
                                            charges with respect to the issue thereof.

 

		e.	No
                                            Conflicts. The execution, delivery and performance of each of the Transaction Documents
                                            by the Company, and the consummation by the Company of the transactions contemplated hereby
                                            and thereby will not (i) result in a violation of the Certificate of Incorporation or the
                                            By-laws (or equivalent constitutive document) of the Company or any of its subsidiaries or
                                            (ii) violate or conflict with, or result in a breach of any provision of, or constitute a
                                            default (or an event which with notice or lapse of time or both would become a default) under,
                                            or give to others any rights of termination, amendment, acceleration or cancellation of,
                                            any agreement, indenture or instrument to which the Company or any subsidiary is a party,
                                            except for those which would not reasonably be expected to have a Material Adverse Effect,
                                            or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including
                                            U.S. federal and state securities laws and regulations) applicable to the Company or any
                                            subsidiary or by which any property or asset of the Company or any subsidiary is bound or
                                            affected except for those which could not reasonably be expected to have a Material Adverse
                                            Effect. Except those which could not reasonably be expected to have a Material Adverse Effect,
                                            neither the Company nor any subsidiary is in violation of any term of or in default under
                                            its constitutive documents. Except those which could not reasonably be expected to have a
                                            Material Adverse Effect, neither the Company nor any subsidiary is in violation of any term
                                            of or in default under any material contract, agreement, mortgage, indebtedness, indenture,
                                            instrument, judgment, decree or order or any statute, rule or regulation applicable to the
                                            Company or any subsidiary. The business of the Company and its subsidiaries is not being
                                            conducted, and shall not be conducted in violation of any law, ordinance, or regulation of
                                            any governmental entity, except for any violation which could not reasonably be expected,
                                            individually or in the aggregate, to have a Material Adverse Effect. Except as specifically
                                            contemplated by this Agreement and as required under the Securities Act and any applicable
                                            state securities laws, neither the Company nor any of its subsidiaries is required to obtain
                                            any consent, authorization or order of, or make any filing or registration with, any court
                                            or governmental agency in order for it to execute, deliver or perform any of its obligations
                                            under or contemplated by this Agreement or the other Transaction Documents in accordance
                                            with the terms hereof or thereof. Neither the execution and delivery by the Company of the
                                            Transaction Documents, nor the consummation by the Company of the transactions contemplated
                                            hereby or thereby, will require any notice, consent or waiver under any contract or instrument
                                            to which the Company or any subsidiary is a party or by which the Company or any subsidiary
                                            is bound or to which any of their assets is subject, except for any notice, consent or waiver
                                            the absence of which would not reasonably be expected, individually or in the aggregate,
                                            to have a Material Adverse Effect and would not adversely affect the consummation of the
                                            transactions contemplated hereby or thereby. All consents, authorizations, orders, filings
                                            and registrations which the Company or any of its subsidiaries is required to obtain pursuant
                                            to the preceding two sentences have been or will be obtained or effected on or prior to the
                                            Closing.

 

    	5

     

    

 

		f.	Absence
                                            of Litigation. There is no action, suit, claim, inquiry, notice of violation, proceeding
                                            (including any partial proceeding such as a deposition) or investigation before or by any
                                            court, public board, governmental or administrative agency, self-regulatory organization,
                                            arbitrator, regulatory authority, stock market, stock exchange or trading facility (an “Action”)
                                            now pending or, to the knowledge of the Company, threatened, against or affecting the Company
                                            or any of its subsidiaries, wherein an unfavorable decision, ruling or finding would (i)
                                            adversely affect the validity or enforceability of, or the authority or ability of the Company
                                            to perform its obligations under this Agreement or any of the other Transaction Documents,
                                            or (ii) have a Material Adverse Effect.

 

		g.	Acknowledgment
                                            Regarding Subscriber’s Purchase of the Units. The Company acknowledges and agrees
                                            that each Subscriber is acting solely in the capacity of an arm’s length purchaser
                                            with respect to the Transaction Documents and the transactions contemplated hereby and thereby.
                                            The Company further acknowledges that each Subscriber is not acting as a financial advisor
                                            or fiduciary of the Company (or in any similar capacity) with respect to the Transaction
                                            Documents and the transactions contemplated hereby and thereby and any advice given by such
                                            Subscriber or any of their respective representatives or agents in connection with the Transaction
                                            Documents and the transactions contemplated hereby and thereby is merely incidental to such
                                            Subscriber’s purchase of the Units (and the Conversion Shares and the Warrant Shares).

 

		h.	No
                                            General Solicitation. Neither the Company, nor any of its “affiliates” (as
                                            defined in Rule 144 under the Securities Act), nor, to the knowledge of the Company, any
                                            person acting on its or their behalf, has engaged in any form of general solicitation or
                                            general advertising (within the meaning of Regulation D) in connection with the offer or
                                            sale of the Units.

 

		i.	No
                                            Integrated Offering. Neither the Company, nor any of its affiliates, nor to the knowledge
                                            of the Company, any person acting on its or their behalf has, directly or indirectly, made
                                            any offers or sales of any security or solicited any offers to buy any security, under circumstances
                                            that would require registration of the Units or the securities contained therein under the
                                            Securities Act or cause this offering of the Units or the securities contained therein to
                                            be integrated with prior offerings by the Company for purposes of the Securities Act.

 

		j.	Employee
                                            Relations. Neither the Company nor any subsidiary is involved in any labor dispute nor,
                                            to the knowledge of the Company, is any such dispute threatened. Neither the Company nor
                                            any subsidiary is party to any collective bargaining agreement. The Company’s and/or
                                            its subsidiaries’ employees are not members of any union, and the Company believes
                                            that its and its subsidiaries’ relationship with their respective employees is good.

 

		k.	Permits.
                                            The Company and its subsidiaries have all authorizations, approvals, clearances, licenses,
                                            permits, certificates or exemptions (including manufacturing approvals and authorizations,
                                            pricing and reimbursement approvals, labeling approvals, registration notifications or their
                                            foreign equivalent) issued by any regulatory authority or governmental agency (collectively,
                                            “Permits”) required to conduct their respective businesses as currently
                                            conducted except to the extent that the failure to have such Permits would not have a Material
                                            Adverse Effect. Except as set forth in the Financial Reports, the Company or its subsidiaries
                                            have fulfilled and performed in all material respects their obligations under each Permit,
                                            and, as of the date hereof, to the knowledge of the Company, no event has occurred or condition
                                            or state of facts exists which would constitute a breach or default or would cause revocation
                                            or termination of any such Permit except to the extent that such breach, default, revocation
                                            or termination would not have a Material Adverse Effect.

 

    	6

     

    

 

		l.	Title.
                                            Except as set forth in Schedule 4(k), each of the Company and its subsidiaries has good and
                                            marketable title to all of its real and personal property and assets, free and clear of any
                                            material restriction, mortgage, deed of trust, pledge, lien, security interest or other charge,
                                            claim or encumbrance which would have a Material Adverse Effect. Except as set forth in the
                                            Financial Reports, with respect to properties and assets it leases, each of the Company and
                                            its subsidiaries is in material compliance with such leases and holds a valid leasehold interest
                                            free of any liens, claims or encumbrances which would have a Material Adverse Effect.

 

		m.	Financial
                                            Statements. The Financial Statements of the Company , as disclosed to the Subscriber
                                            as part of the Disclosure Materials, comply in all material respects with applicable accounting
                                            requirements and the rules and regulations of the U.S. generally accepted accounting principles
                                            (“GAAP”) with respect thereto as in effect at the time of filing. Such financial
                                            statements have been prepared in accordance with GAAP applied on a consistent basis during
                                            the periods involved, except as may be otherwise specified in such financial statements or
                                            the notes thereto and except that unaudited financial statements may not contain all footnotes
                                            required by GAAP, and fairly present in all material respects the financial position of the
                                            Company and its consolidated subsidiaries taken as a whole as of and for the dates thereof
                                            and the results of operations and cash flows for the periods then ended, subject, in the
                                            case of unaudited statements, to normal, year-end audit adjustments. [The pro forma financial
                                            information and the related notes, if any, included in the Financial Statements have been
                                            properly compiled and prepared in accordance with the applicable requirements of the Securities
                                            Act and the regulations promulgated thereunder and fairly present in all material respects
                                            the information shown therein, and the assumptions used in the preparation thereof are reasonable
                                            and the adjustments used therein are appropriate to give effect to the transactions and circumstances
                                            referred to therein.

 

		n.	Rights
                                            of First Refusal. The Company is not obligated to offer the securities offered hereunder
                                            on a right of first refusal basis or otherwise to any third parties including, but not limited
                                            to, current or former stockholders of the Company, underwriters, brokers, agents or other
                                            third parties.

 

		o.	Reliance.
                                            The Company acknowledges that the Subscriber is relying on the representations and warranties
                                            made by the Company hereunder and that such representations and warranties are a material
                                            inducement to the Subscriber purchasing the Units. The Company further acknowledges that
                                            without such representations and warranties of the Company made hereunder, the Subscribers
                                            would not enter into this Agreement.

 

		p.	Material
                                            Changes. Since the respective date of the latest balance sheet included in the Financial
                                            Statements, except as specifically disclosed herein or in the Financial Statements, (i)there
                                            have been no events, occurrences or developments that have had or would reasonably be expected
                                            to have a Material Adverse Effect with respect to the Company, (ii) there have not been any
                                            changes in the authorized capital, assets, financial condition, business or operations of
                                            the Company from that reflected in the financial statements contained within the Financial
                                            Statements except changes in the ordinary course of business which have not been, either
                                            individually or in the aggregate, materially adverse to the business, properties, financial
                                            condition or results of operations of the Company, (iii) neither the Company or any subsidiary
                                            has incurred any material liabilities (contingent or otherwise) other than (A) trade payables,
                                            accrued expenses and other liabilities incurred in the ordinary course of business consistent
                                            with past practice and (B) liabilities not required to be reflected in the financial statements
                                            of the Company, as applicable, pursuant to GAAP or to be disclosed in the Financial Statements,
                                            (iv) neither the Company nor any subsidiary has materially altered its method of accounting
                                            or the manner in which it keeps its accounting books and records, and (v) neither the Company
                                            or any subsidiary has declared or made any dividend or distribution of cash or other property
                                            to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any
                                            shares of its capital stock (other than in connection with repurchases of unvested stock
                                            issued to employees of the Company).

 

    	7

     

    

 

		q.	Brokers’
                                            Fees. The Company does not have any liability or obligation to pay any fees or commissions
                                            to any broker, finder or agent with respect to the transactions contemplated by this Agreement,
                                            except for the payment of fees to the Placement Agent as described above.

 

		r.	Off-Balance
                                            Sheet Arrangements. There is no transaction, arrangement, or other relationship between
                                            the Company or any subsidiary and an unconsolidated or other off-balance sheet entity that
                                            is required to be disclosed by the Company in the Financial Statements and is not so disclosed
                                            or that otherwise would have a Material Adverse Effect.

 

		s.	Investment
                                            Company. The Company is not required to be registered as, and is not an affiliate of,
                                            and immediately following the Closing will not be required to register as, an “investment
                                            company” within the meaning of the Investment Company Act of 1940, as amended.

 

		t.	Reliance.
                                            The Company acknowledges that the Purchaser is relying on the representations and warranties
                                            made by the Company hereunder and that such representations and warranties are a material
                                            inducement to the Purchaser purchasing the Shares. The Company further acknowledges that
                                            without such representations and warranties of the Company made hereunder, the Purchaser
                                            would not enter into this Agreement.

 

	5.	Representations,
                                            Warranties and Agreements of the Subscriber. The Subscriber represents and warrants to,
                                            and agrees with, the Company the following:

 

		a.	The
                                            Subscriber, its advisers, if any, and its designated representatives, if any, have the knowledge
                                            and experience in financial and business matters necessary to evaluate the merits and risks
                                            of its prospective investment in the Company, and have carefully reviewed and understand
                                            the risks of, and other considerations relating to, the purchase of Units and the tax consequences
                                            of the investment, and have the ability to bear the economic risks of the investment.

 

		b.	The
                                            Subscriber is acquiring the Units, and upon conversion of the Shares, the Conversion Shares,
                                            and upon exercise of the Warrants, the Warrant Shares, for investment for its own account
                                            and not with the view to, or for resale in connection with, any distribution thereof. The
                                            Subscriber understands and acknowledges that the Offering and sale of the Units, the Shares
                                            and the Warrants have not been, and the Conversion Shares and the Warrant Shares will not
                                            be, registered under the Securities Act or any state securities laws, by reason of a specific
                                            exemption from the registration provisions of the Securities Act and applicable state securities
                                            laws, which depends upon, among other things, the bona fide nature of the investment intent
                                            as expressed herein. The Subscriber further represents that it does not have any contract,
                                            undertaking, agreement or arrangement with any person to sell, transfer or grant participation
                                            to any third person with respect to any of the Units, the Shares, the Conversion Shares,
                                            the Warrants or the Warrant Shares. The Subscriber understands and acknowledges that the
                                            offering of the Units pursuant to this Agreement will not be registered under the Securities
                                            Act nor under the state securities laws on the ground that the sale provided for in this
                                            Agreement and the issuance of securities hereunder is exempt from the registration requirements
                                            of the Securities Act and any applicable state securities laws.

 

    	8

     

    

 

		c.	The
                                            Subscriber is an “accredited investor” as defined in Rule 501 of Regulation D
                                            as promulgated by the SEC under the Securities Act, for the reason(s) specified on the Accredited
                                            Investor Certification attached hereto as completed by Subscriber, and Subscriber
                                            shall submit to the Company such further assurances of such status as may be reasonably requested
                                            by the Company. The Subscriber further acknowledges and understands that it is required to
                                            be an “accredited investor” at the time it exercises the Warrants. The Subscriber
                                            resides in the jurisdiction set forth on the Subscriber’s Omnibus Signature Page affixed
                                            hereto. The Purchaser has not taken any of the actions set forth in, and is not subject to,
                                            the disqualification provisions of Rule 506(d)(1) of the Securities Act.

 

		d.	The
                                            Subscriber (i) if a natural person, represents that he or she is the greater of (A) 21 years
                                            of age or (B) the age of legal majority in his or her jurisdiction of residence, and has
                                            full power and authority to execute and deliver this Agreement and all other related agreements
                                            or certificates and to carry out the provisions hereof and thereof; (ii) if a corporation,
                                            partnership, or limited liability company or partnership, or association, joint stock company,
                                            trust, unincorporated organization or other entity, represents that such entity was not formed
                                            for the specific purpose of acquiring the Units, such entity is duly organized, validly existing
                                            and in good standing under the laws of the state or jurisdiction of its organization, the
                                            consummation of the transactions contemplated hereby is authorized by, and will not result
                                            in a violation of state law or its charter or other organizational documents, such entity
                                            has full power and authority to execute and deliver this Agreement and all other related
                                            agreements or certificates and to carry out the provisions hereof and thereof and to purchase
                                            and hold the Units, the execution and delivery of this Agreement has been duly authorized
                                            by all necessary action, this Agreement has been duly executed and delivered on behalf of
                                            such entity and is a legal, valid and binding obligation of such entity; or (iii) if executing
                                            this Agreement in a representative or fiduciary capacity, represents that it has full power
                                            and authority to execute and deliver this Agreement in such capacity and on behalf of the
                                            subscribing individual, ward, partnership, trust, estate, corporation, or limited liability
                                            company or partnership, or other entity for whom the Subscriber is executing this Agreement,
                                            and such individual, partnership, ward, trust, estate, corporation, or limited liability
                                            company or partnership, or other entity has full right and power to perform pursuant to this
                                            Agreement and make an investment in the Company, and represents that this Agreement constitutes
                                            a legal, valid and binding obligation of such entity. The execution and delivery of this
                                            Agreement will not violate or be in conflict with any order, judgment, injunction, agreement
                                            or controlling document to which the Subscriber is a party or by which it is bound.

 

		e.	The
                                            Subscriber understands that the Units are being offered and sold to it in reliance on specific
                                            exemptions from the registration requirements of United States federal and state securities
                                            laws and that the Company is relying in part upon the truth and accuracy of, and such Subscriber’s
                                            compliance with, the representations, warranties, agreements, acknowledgments and understandings
                                            of such Subscriber set forth herein in order to determine the availability of such exemptions
                                            and the eligibility of such Subscriber to acquire such securities. The Subscriber further
                                            acknowledges and understands that the Company is relying on the representations and warranties
                                            made by the Subscriber hereunder and that such representations and warranties are a material
                                            inducement to the Company to sell the Units to the Subscriber. The Subscriber further acknowledges
                                            that without such representations and warranties of the Subscriber made hereunder, the Company
                                            would not enter into this Agreement with the Subscriber.

 

    	9

     

    

 

		f.	The
                                            Subscriber understands that no public market now exists, and that there will never be a public
                                            market for, the Units or the Warrants, and that there can be no assurance that an active
                                            public market for the Common Stock will develop or otherwise be established in the future.

 

		g.	The
                                            Subscriber, its advisers, if any, and its designated representatives, if any, have received
                                            and reviewed information about the Company, including all Disclosure Materials, and have
                                            had an opportunity to discuss the Company’s business, management and financial affairs
                                            with the Company’s management. The Subscriber understands that such discussions, as
                                            well as any Disclosure Material provided by the Company, were intended to describe the aspects
                                            of the Company’s business and prospects which the Company believes to be material,
                                            but were not necessarily a thorough or exhaustive description, and except as expressly set
                                            forth in this Agreement, the Company makes no representation or warranty with respect to
                                            the completeness of such information and makes no representation or warranty of any kind
                                            with respect to any information provided by any entity other than the Company. Some of such
                                            information may include projections as to the future performance of the Company, which projections
                                            may not be realized, may be based on assumptions which may not be correct and may be subject
                                            to numerous factors beyond the Company’s control. Additionally, the Subscriber understands
                                            and represents that it is purchasing the Units notwithstanding the fact that the Company
                                            may disclose in the future certain material information the Subscriber has not received,
                                            including (without limitation) financial statements of the Company a for the current or prior
                                            fiscal periods, and any subsequent period financial statements that will be filed with the
                                            Securities and Exchange Commission, that it is not relying on any such information in connection
                                            with its purchase of the Units and that it waives any right of action with respect to the
                                            nondisclosure to it prior to its purchase of the Units of any such information. Each Subscriber
                                            has sought such accounting, legal and tax advice as it has considered necessary to make an
                                            informed investment decision with respect to its acquisition of the Units.

 

		h.	The
                                            Subscriber acknowledges that the Company is not acting as a financial advisor or fiduciary
                                            of the Subscriber (or in any similar capacity) with respect to the Transaction Documents
                                            and the transactions contemplated hereby and thereby and no investment advice has been given
                                            by the Company or any of its representatives or agents in connection with the Transaction
                                            Documents and the transactions contemplated hereby and thereby. The Subscriber further represents
                                            to the Company that the Subscriber’s decision to enter into the Transaction Documents
                                            has been based solely on the independent evaluation by the Subscriber and its representatives.

 

		i.	As
                                            of the Closing, all actions on the part of Subscriber, and its officers, directors and partners,
                                            if applicable, necessary for the authorization, execution and delivery of this Agreement
                                            and the Registration Rights Agreement and the performance of all obligations of the Subscriber
                                            hereunder and thereunder shall have been taken, and this Agreement and the Registration Rights
                                            Agreement, assuming due execution by the parties hereto and thereto, constitute valid and
                                            legally binding obligations of the Subscriber, enforceable in accordance with their respective
                                            terms, subject to: (i) judicial principles limiting the availability of specific performance,
                                            injunctive relief, and other equitable remedies and (ii) bankruptcy, insolvency, reorganization,
                                            moratorium or other similar laws now or hereafter in effect generally relating to or affecting
                                            creditors’ rights.

 

    	10

     

    

 

		j.	Subscriber
                                            represents that neither it nor, to its knowledge, any person or entity controlling, controlled
                                            by or under common control with it, nor any person having a beneficial interest in it, nor
                                            any person on whose behalf the Subscriber is acting: (i) is a person listed in the Annex
                                            to Executive Order No. 13224 (2001) issued by the President of the United States (Executive
                                            Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to
                                            Commit, or Support Terrorism); (ii) is named on the List of Specially Designated Nationals
                                            and Blocked Persons maintained by the U.S. Office of Foreign Assets Control; (iii) is a non-U.S.
shell bank or is providing banking services indirectly to a non-U.S. shell bank; (iv) is a senior non-U.S. political figure or an
immediate family member or close associate of such figure; or (v) is otherwise prohibited from investing in the Company pursuant to
applicable U.S. anti-money laundering, anti-terrorist and asset control laws, regulations, rules or orders (categories (i) through
(v), each a “Prohibited Subscriber”). The Subscriber agrees to provide the Company, promptly upon request,
all information that the Company reasonably deems necessary or appropriate to comply with applicable U.S. anti-money laundering,
anti-terrorist and asset control laws, regulations, rules and orders. The Subscriber consents to the disclosure to U.S. regulators
and law enforcement authorities by the Company and its affiliates and agents of such information about the Subscriber as the Company
reasonably deems necessary or appropriate to comply with applicable U.S. anti-money laundering, anti- terrorist and asset control
laws, regulations, rules and orders. If the Subscriber is a financial institution that is subject to the USA Patriot Act, the
Subscriber represents that it has met all of its obligations under the USA Patriot Act. The Subscriber acknowledges that if,
following its investment in the Company, the Company reasonably believes that the Subscriber is a Prohibited Subscriber or is
otherwise engaged in suspicious activity or refuses to promptly provide information that the Company requests, the Company has the
right or may be obligated to prohibit additional investments, segregate the assets constituting the investment in accordance with
applicable regulations or immediately require the Subscriber to transfer the Shares, the Conversion Shares, the Warrants and/or the
Warrant Shares. The Subscriber further acknowledges that the Subscriber will have no claim against the Company or any of its
affiliates or agents for any form of damages as a result of any of the foregoing actions.
	 	 	 
	 	 	If
the Subscriber is affiliated with a non-U.S. banking institution (a “Foreign Bank”), or if the Subscriber
receives deposits from, makes payments on behalf of, or handles other financial transactions related to a Foreign Bank, the
Subscriber represents and warrants to the Company that: (1) the Foreign Bank has a fixed address, other than solely an electronic
address, in a country in which the Foreign Bank is authorized to conduct banking activities; (2) the Foreign Bank maintains
operating records related to its banking activities; (3) the Foreign Bank is subject to inspection by the banking authority that
licensed the Foreign Bank to conduct banking activities; and (4) the Foreign Bank does not provide banking services to any other
Foreign Bank that does not have a physical presence in any country and that is not a regulated affiliate.

 

		k.	The
                                            Subscriber or its duly authorized representative recognizes that, as the Company is in its
                                            early stages of development and, as there has yet to develop a public or private market in
                                            the Company’s securities, there can be no assurance that any such market will develop
                                            in the foreseeable future. Furthermore, there can be no assurance that the Company will ever
                                            consummate a public offering or become an SEC-reporting issuer. The Subscriber has carefully
                                            considered such risk before deciding to invest in the Shares.

 

		l.	The
                                            Subscriber has adequate means of providing for its current and anticipated financial needs
                                            and contingencies, is able to bear the economic risk for an indefinite period of time and
                                            has no need for liquidity of the investment in the Units and could afford complete loss of
                                            such investment.

 

    	11

     

    

 

		m.	The
                                            Subscriber is not subscribing for Units as a result of or subsequent to any advertisement,
                                            article, notice or other communication, published in any newspaper, magazine or similar media
                                            or broadcast over television, radio, or the internet, or presented at any seminar or meeting,
                                            or any solicitation of a subscription by a person not previously known to the Subscriber
                                            in connection with investments in securities generally.

 

		n.	The
                                            Subscriber acknowledges that no U.S. federal or state agency or any other government or governmental
                                            agency has passed upon the Units, the Shares, the Conversion Shares, the Warrants or the
                                            Warrant Shares or made any finding or determination as to the fairness, suitability or wisdom
                                            of any investments therein.

 

		o.	Other
                                            than consummating the transactions contemplated hereunder, the Subscriber has not directly
                                            or indirectly, nor has any individual or entity acting on behalf of or pursuant to any understanding
                                            with such Subscriber, executed any purchases or sales, including Short Sales, of the securities
                                            of the Company during the period commencing as of the time that such Subscriber first received
                                            a term sheet (written or oral) from the Company or any other individual or entity representing
                                            the Company setting forth the material terms of the transactions contemplated hereunder and
                                            ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case
                                            of a Subscriber that is a multi-managed investment vehicle whereby separate portfolio managers
                                            manage separate portions of such Subscriber’s assets and the portfolio managers have
                                            no direct knowledge of the investment decisions made by the portfolio managers managing other
                                            portions of such Subscriber’s assets, the representation set forth above shall only
                                            apply with respect to the portion of assets managed by the portfolio manager that made the
                                            investment decision to purchase the Shares covered by this Agreement. Other than to other
                                            individuals or entities party to this Agreement, such Subscriber has maintained the confidentiality
                                            of all disclosures made to it in connection with this transaction (including the existence
                                            and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing
                                            contained herein shall constitute a representation or warranty, or preclude any actions,
                                            with respect to the identification of the availability of, or securing of, available shares
                                            to borrow in order to effect Short Sales or similar transactions in the future. For purposes
                                            of this Agreement, “Short Sales” means all “short sales”
                                            as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed
                                            to include the location and/or reservation of borrowable shares of Common Stock).

 

		p.	The
                                            Subscriber agrees to be bound by all of the terms and conditions of the Registration Rights
                                            Agreement and the Warrants and to perform all obligations thereby imposed upon it.

 

		q.	The
                                            Subscriber is aware that the anti-manipulation rules of Regulation M under the Exchange Act
                                            may apply to sales of the Conversion Shares and Warrant Shares and other activities with
                                            respect to such shares held by the Subscriber.

 

		r.	All
                                            of the information concerning the Subscriber set forth herein, and any other information
                                            furnished by the Subscriber in writing to the Company or the Placement Agent for use in connection
                                            with the transactions contemplated by this Agreement, or which is set forth herein is true,
                                            correct and complete in all material respects as of the date of this Agreement, and, if there
                                            should be any material change in such information prior to the admission of the undersigned
                                            to the Company, the Subscriber will immediately furnish revised or corrected information
                                            to the Company.

 

    	12

     

    

 

		s.	(For
                                            ERISA plans only) The fiduciary of the ERISA plan (the “Plan”)
                                            represents that such fiduciary has been informed of and understands the Company’s investment
                                            objectives, policies and strategies, and that the decision to invest “plan assets”
                                            (as such term is defined in ERISA) in the Company is consistent with the provisions of ERISA
                                            that require diversification of plan assets and impose other fiduciary responsibilities.
                                            The Subscriber fiduciary or Plan (a) is responsible for the decision to invest in the Company;
                                            (b) is independent of the Company or any of its affiliates; (c) is qualified to make such
                                            investment decision; and (d) in making such decision, the Subscriber fiduciary or Plan has
                                            not relied primarily on any advice or recommendation of the Company or any of its affiliates.

 

	6.	Transfer
                                            Restrictions. The Subscriber acknowledges and agrees as follows:

 

		a.	The
                                            Units, the Shares, the Conversion Shares, the Warrants and the Warrant Shares have not been
                                            registered for sale under the Securities Act, in reliance on the private offering exemption
                                            in Section 4(a)(2) thereof; other than as expressly provided for in the Registration Rights
                                            Agreement, the Company does not currently intend to register the Units, the Shares, the Conversion
                                            Shares, the Warrants or the Warrant Shares under the Securities Act at any time in the future;
                                            and the undersigned will not immediately be entitled to the benefits of Rule 144 with respect
                                            to the Units, the Conversion Shares, the Shares, the Warrants and the Warrant Shares.

 

		b.	The
                                            Subscriber understands that there are substantial restrictions on the transferability of
                                            the Shares, the Conversion Shares, the Warrants and the Warrant Shares (collectively, the
                                            “Securities”), that the certificates representing the Securities
                                            shall bear a restrictive legend in substantially the following form (or in the case of the
                                            Warrants, as shown on the form of Warrant attached hereto) (and a stop-transfer order may
                                            be placed against transfer of such certificates or other instruments):

 

THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), OR ANY STATE SECURITIES LAWS, AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED
OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE SECURITIES ACT AND ANY APPLICABLE
STATE SECURITIES LAWS, OR (2) AN EXEMPTION FROM SUCH REGISTRATION EXISTS AND THE COMPANY RECEIVES AN OPINION OF COUNSEL, WHICH COUNSEL
AND OPINION ARE SATISFACTORY TO THE COMPANY, THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR TRANSFERRED IN THE MANNER
CONTEMPLATED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR APPLICABLE STATE SECURITIES LAWS. HEDGING TRANSACTIONS
INVOLVING THESE SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT.

 

In
addition, if any Subscriber is an affiliate of the Company certificates evidencing the Shares issued to such Subscriber may bear a customary
“Affiliates” legend.

 

The
legend set forth above shall be removed and the Company shall issue a certificate without such legend to the holder of the Securities
upon which it is stamped, if (a) such Shares are sold pursuant to a registration statement under the Securities Act, or (b) such holder
delivers to the Company an opinion of counsel, reasonably acceptable to the Company, that a disposition of the Securities is being made
pursuant to an exemption from such registration and that the Securities, after such transfer, shall no longer be “restricted securities”
within the meaning of Rule 144.

 

    	13

     

    

 

	7.	Conditions
                                            to Company’s Obligations at Closing. The Company’s obligation to complete
                                            the sale and issuance of the Units and deliver the shares of Series A Preferred Stock and
                                            the Warrants to each Subscriber, individually, at each Closing shall be subject to the following
                                            conditions to the extent not waived by the Company:

 

	 	a.	Receipt
    of Payment. The Company shall have received payment, by certified or other bank check or by wire transfer of immediately available
    funds, in the full amount of the Purchase Price for the number of Units being purchased by such Subscriber at such Closing.
	 	 	 
	 	b.	Representations
    and Warranties. The representations and warranties made by the Subscribers in Section 5 hereof shall be true and correct
    in all material respects when made, and shall be true and correct in all material respects on such Closing Date with the same force
    and effect as if they had been made on and as of said date (except in each case to the extent any such representation and warranty
    is qualified by materiality, in which case, such representation and warranty shall be true and correct in all respects as so qualified).
    The Subscriber shall have performed in all material respects all obligations and covenants herein required to be performed by them
    on or prior to such Closing Date.
	 	 	 
	 	c.	Receipt
    of Executed Documents. Such Subscriber shall have executed and delivered to the Company the Omnibus Signature Page, the Investor
    Profile, Anti-Money Laundering Form and Accredited Investor Certification.
	 	 	 
	 	d.	Minimum
    Offering. The initial Closing shall be at least for the number of Units in the Minimum Offering at the Purchase Price.
	 	 	 
	 	e.	Certificate
    of Designations. The Certificate of Designations shall have been filed with the Secretary of State of the State of Delaware.
	 	 	 
	 	f.	Judgments.
    No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including any bankruptcy
    court or judge, or any order of or by any governmental authority, shall have been issued, and no action or proceeding shall have
    been instituted by any governmental authority, enjoining or preventing the consummation of the transactions contemplated hereby.
	 	 	 
	 	g.	No
    Short Selling. In addition, each Subscriber shall have entered into agreements with the Company whereby they will agree that
    they will not, for a period of 12 months following the first Closing Date, directly or indirectly, effect or agree to effect any
    short sale (as defined in Rule 200 under Regulation SHO of the Exchange Act), whether or not against the box, establish any “put
    equivalent position” (as defined in Rule 16a-1(h) under the Exchange Act) with respect to the Common Stock, borrow or pre-borrow
    any shares of Common Stock, or grant any other right (including, without limitation, any put or call option) with respect to the
    Common Stock or with respect to any security that includes, relates to or derives any significant part of its value from the Common
    Stock or otherwise seek to hedge its position in the Common Stock.

 

    	14

     

    

 

	8.	Conditions
                                            to Subscribers’ Obligations at Closing. Each Subscriber’s obligation to accept
                                            delivery of the shares of Series A Preferred Stock and the Warrants and to pay for the Units
                                            at each Closing shall be subject to the following conditions to the extent not waived by
                                            the Subscribers:

 

		a.	Representations
                                            and Warranties Correct. The representations and warranties made by the Company in Section
                                            4 hereof shall be true and correct in all material respects (except to the extent any such
                                            representation and warranty is qualified by materiality or reference to Material Adverse
                                            Effect, in which case, such representation and warranty shall be true and correct in all
                                            respects as so qualified) as of, and as if made on, the date of this Agreement and as of
                                            such Closing Date, except to the extent any such representation or warranty expressly speaks
                                            as of an earlier date, in which case such representation or warranty shall be true and in
                                            all material respects correct as of such earlier date (except in each case to the extent
                                            any such representation and warranty is qualified by materiality or reference to Material
                                            Adverse Effect, in which case, such representation and warranty shall be true and correct
                                            in all respects as so qualified). The Company shall have performed in all material respects
                                            all obligations and covenants herein required to be performed by it on or prior to such Closing
                                            Date.

 

		b.	Receipt
                                            of Executed Transaction Documents. The Company shall have executed and delivered to the
                                            Placement Agent the Registration Rights Agreement and the Escrow Agreement.

 

		c.	Minimum
                                            Offering. The initial Closing shall be at least for the number of shares of Common Stock
                                            in the Minimum Offering at the Purchase Price.

 

		d.	Certificate
                                            of Designations. The Certificate of Designations shall have been filed with the Secretary
                                            of State of the State of Delaware.

 

		e.	Judgments.
                                            No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice
                                            or magistrate, including any bankruptcy court or judge, or any order of or by any governmental
                                            authority, shall have been issued, and no action or proceeding shall have been instituted
                                            by any governmental authority, enjoining or preventing the consummation of the transactions
                                            contemplated hereby.

 

		f.	No
                                            Short Selling Agreements. Each of the agreements required by Section 7g hereto shall
                                            have been executed by the persons referred to therein and delivered to the Company.

 

	9.	Indemnification.
                                            The Subscriber agrees to indemnify and hold harmless the Company, the Placement Agent
                                            and any other broker, agent or finder engaged by the Company for the Offering, and their
                                            respective directors, officers, shareholders, members, partners, employees and agents (and
                                            any other persons with a functionally equivalent role of a person holding such titles notwithstanding
                                            a lack of such title or any other title), each person who controls such Purchaser (within
                                            the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and
                                            the directors, officers, shareholders, agents, members, partners or employees (and any other
                                            persons with a functionally equivalent role of a person holding such titles notwithstanding
                                            a lack of such title or any other title) of such controlling person, from and against all
                                            losses, liabilities, claims, damages, costs, fees and expenses whatsoever (including, but
                                            not limited to, any and all expenses incurred in investigating, preparing or defending against
                                            any litigation commenced or threatened) based upon or arising out of the Subscriber’s
                                            actual or alleged false acknowledgment, representation or warranty, or misrepresentation
                                            or omission to state a material fact, or breach by the Subscriber of any covenant or agreement
                                            made by the Subscriber, contained herein or in any other any other Disclosure Materials.

 

    	15

     

    

 

	10.	Revocability;
                                            Binding Effect. The subscription hereunder may be revoked prior to the Closing thereon,
                                            provided that written notice of revocation is sent and is received by the Company or either
                                            of the Placement Agent at least two Business Days prior to the Closing on such subscription.
                                            The Subscriber hereby acknowledges and agrees that this Agreement shall survive the death
                                            or disability of the Subscriber and shall be binding upon and inure to the benefit of the
                                            parties and their heirs, executors, administrators, successors, legal representatives and
                                            permitted assigns. If the Subscriber is more than one person, the obligations of the Subscriber
                                            hereunder shall be joint and several and the agreements, representations, warranties and
                                            acknowledgments herein shall be deemed to be made by and be binding upon each such person
                                            and such person’s heirs, executors, administrators, successors, legal representatives
                                            and permitted assigns.

 

	11.	Modification.
                                            This Agreement shall not be modified or waived except by an instrument in writing signed
                                            by the party against whom any such modification or waiver is sought to be enforced.

 

	12.	Immaterial
                                            Modifications to the Registration Rights Agreement. The Company may, at any time prior
                                            to the initial Closing, amend the Registration Rights Agreement if necessary to clarify any
                                            provision therein, without first providing notice or obtaining prior consent of the Subscriber.

 

	13.	Third-Party
                                            Beneficiary. The Placement Agent shall be an express third-party beneficiary of the representations
                                            and warranties included in this Agreement. This Agreement is intended for the benefit of
                                            the parties hereto and their respective successors and permitted assigns and is not for the
                                            benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise
                                            set forth in Section 9 and this Section.

 

	14.	Notices.
                                            Any notice or other communication required or permitted to be given hereunder shall be
                                            in writing and shall be mailed by certified mail, return receipt requested, or delivered
                                            against receipt to the party to whom it is to be given (a) if to the Company, at the address
                                            set forth above, with a copy to CKR Law LLP, 1330 Avenue of the Americas, New York, New York
                                            10019, Attention: Jeffrey A. Rinde, facsimile +1-212-259-8200 or (b) if to the Subscriber,
                                            at the address set forth on the Omnibus Signature Page hereof (or, in either case, to such
                                            other address as the party shall have furnished in writing in accordance with the provisions
                                            of this Section). Any notice or other communication given by certified mail shall be deemed
                                            given at the time of certification thereof, except for a notice changing a party’s
                                            address which shall be deemed given at the time of receipt thereof.

 

	15.	Assignability.
                                            This Agreement and the rights, interests and obligations hereunder are not transferable
                                            or assignable by the Subscriber, and the transfer or assignment of the Units, the Shares,
                                            the Conversion Shares, the Warrants or the Warrant Shares shall be made only in accordance
                                            with all applicable laws.

 

	16.	Applicable
                                            Law. This Agreement shall be governed by and construed in accordance with the laws of
                                            the State of New York, without reference to the principles thereof relating to the conflict
                                            of laws.

 

	17.	Arbitration.
                                            The parties agree to submit all controversies to arbitration in accordance with the provisions
                                            set forth below and understand that:

 

		a.	Arbitration
                                            shall be final and binding on the parties.

 

		b.	The
                                            parties are waiving their right to seek remedies in court, including the right to a jury
                                            trial.

 

		c.	Pre-arbitration
                                            discovery is generally more limited and different from court proceedings.

 

    	16

     

    

 

		d.	The
                                            arbitrator’s award is not required to include factual findings or legal reasoning and
                                            any party’s right to appeal or to seek modification of rulings by arbitrators is strictly
                                            limited.

 

		e.	The
                                            panel of arbitrators will typically include a minority of arbitrators who were or are affiliated
                                            with the securities industry.

 

		f.	All
                                            controversies which may arise between the parties concerning this Agreement shall be determined
                                            by arbitration pursuant to the rules then pertaining to the Financial Industry Regulatory
                                            Authority in New York City, New York. Judgment on any award of any such arbitration may be
                                            entered in the Supreme Court of the State of New York or in any other court having jurisdiction
                                            of the person or persons against whom such award is rendered. Any notice of such arbitration
                                            or for the confirmation of any award in any arbitration shall be sufficient if given in accordance
                                            with the provisions of this Agreement. The parties agree that the determination of the arbitrators
                                            shall be binding and conclusive upon them. The prevailing party, as determined by such arbitrators,
                                            in a legal proceeding shall be entitled to collect any costs, disbursements and reasonable
                                            attorney’s fees from the other party. Prior to filing an arbitration, the parties hereby
                                            agree that they will attempt to resolve their differences first by submitting the matter
                                            for resolution to a mediator, acceptable to all parties, and whose expenses will be borne
                                            equally by all parties. The mediation will be held in the County of New York, State of New
                                            York, on an expedited basis. If the parties cannot successfully resolve their differences
                                            through mediation, the matter will be resolved by arbitration. The arbitration shall take
                                            place in the County of New York, State of New York, on an expedited basis.

 

	18.	Blue
                                            Sky Qualification. The purchase of Units under this Agreement is expressly conditioned
                                            upon the exemption from qualification of the offer and sale of the Units from applicable
                                            federal and state securities laws. The Company shall not be required to qualify this transaction
                                            under the securities laws of any jurisdiction and, should qualification be necessary, the
                                            Company shall be released from any and all obligations to maintain its offer, and may rescind
                                            any sale contracted, in the jurisdiction.

 

	19.	Use
                                            of Pronouns. All pronouns and any variations thereof used herein shall be deemed to refer
                                            to the masculine, feminine, neuter, singular or plural as the identity of the person or persons
                                            referred to may require.

 

	20.	Confidentiality.
                                            The Subscriber acknowledges and agrees that any information or data the Subscriber has
                                            acquired from or about the Company or may acquire in the future, not otherwise properly in
                                            the public domain, including, without limitation, the Disclosure Materials, was received
                                            in confidence. The Subscriber agrees not to divulge, communicate or disclose, except as may
                                            be required by law or for the performance of this Agreement, or use to the detriment of the
                                            Company or for the benefit of any other person, or misuse in any way, any confidential information
                                            of the Company, including any scientific, technical, trade or business secrets of the Company
                                            and any scientific, technical, trade or business materials that are treated by the Company
                                            as confidential or proprietary, including, but not limited to, internal personnel and financial
                                            information of the Company or its affiliates, the manner and methods of conducting the business
                                            of the Company or its affiliates and confidential information obtained by or given to the
                                            Company about or belonging to third parties. The Subscriber understands that the Company
                                            may rely on Subscriber’s agreement of confidentiality to comply with the exemptive
                                            provisions of Regulation FD under the Securities Act of 1933 as set forth in Rule 100(a)(b)(2)(ii)
                                            of Regulation FD. In addition, the Subscriber acknowledges that it is aware that the United
                                            States securities laws generally prohibit any person who is in possession of material nonpublic
                                            information about a public company such as the Company from purchasing or selling securities
                                            of such company. The provisions of this Section 17 are in addition to and not in replacement
                                            of any other confidentiality agreement between the Company and the Subscriber.

 

    	17

     

    

 

	21.	Miscellaneous.

 

		a.	This
                                            Agreement, together with the Registration Rights Agreement, the Warrant and any confidentiality
                                            agreement between the Purchaser and the Company, constitute the entire agreement between
                                            the Subscriber and the Company with respect to the Offering and supersede all prior oral
                                            or written agreements and understandings, if any, relating to the subject matter hereof.
                                            The terms and provisions of this Agreement may be waived, or consent for the departure therefrom
                                            granted, only by a written document executed by the party entitled to the benefits of such
                                            terms or provisions.

 

		b.	The
                                            representations and warranties of the Company and the Subscriber made in this Agreement shall
                                            survive the execution and delivery hereof and delivery of the Common Stock and the Warrants
                                            contained in the Units for a period of twelve (12) months following the Closing Date.

 

		c.	Each
                                            of the parties hereto shall pay its own fees and expenses (including the fees of any attorneys,
                                            accountants, appraisers or others engaged by such party) in connection with this Agreement
                                            and the transactions contemplated hereby, whether or not the transactions contemplated hereby
                                            are consummated.

 

		d.	This
                                            Agreement may be executed in one or more original or facsimile or by an e-mail which contains
                                            a portable document format (.pdf) file of an executed signature page counterparts, each of
                                            which shall be deemed an original, but all of which shall together constitute one and the
                                            same instrument and which shall be enforceable against the parties actually executing such
                                            counterparts. The exchange of copies of this Agreement and of signature pages by facsimile
                                            transmission or in .pdf format shall constitute effective execution and delivery of this
                                            Agreement as to the parties and may be used in lieu of the original Agreement for all purposes.
                                            Signatures of the parties transmitted by facsimile or by e-mail of a document in pdf format
                                            shall be deemed to be their original signatures for all purposes.

 

		e.	Each
                                            provision of this Agreement shall be considered separable and, if for any reason any provision
                                            or provisions hereof are determined to be invalid or contrary to applicable law, such invalidity
                                            or illegality shall not impair the operation of or affect the remaining portions of this
                                            Agreement.

 

		f.	Paragraph
                                            titles are for descriptive purposes only and shall not control or alter the meaning of this
                                            Agreement as set forth in the text.

 

		g.	The
                                            Subscriber understands and acknowledges that there may be multiple Closings for the Offering.

 

		h.	The
                                            Subscriber hereby agrees to furnish the Company such other information as the Company may
                                            request prior to the Closing with respect to its subscription hereunder.

 

		i.	The
                                            representations and warranties of the Company and the Purchaser made in this Agreement shall
                                            survive the execution and delivery hereof and the delivery of the Shares for a period of
                                            twelve (12) months following the first Closing Date.

 

    	18

     

    

 

	22.	Omnibus
                                            Signature Page. This Agreement is intended to be read and construed in conjunction with
                                            the Registration Rights Agreement. Accordingly, pursuant to the terms and conditions of this
                                            Agreement and the Registration Rights Agreement, it is hereby agreed that the execution by
                                            the Subscriber of this Agreement, in the place set forth on the Omnibus Signature Page below,
                                            shall constitute agreement to be bound by the terms and conditions hereof and the terms and
                                            conditions of the Registration Rights Agreement, with the same effect as if each of such
                                            separate but related agreement were separately signed.

 

	23.	Public
                                            Disclosure. Neither the Subscriber nor any officer, manager, director, member, partner,
                                            stockholder, employee, affiliate, affiliated person or entity of the Subscriber shall make
                                            or issue any press releases or otherwise make any public statements or make any disclosures
                                            to any third person or entity with respect to the transactions contemplated herein and will
                                            not make or issue any press releases or otherwise make any public statements of any nature
                                            whatsoever with respect to the Company without the Company’s express prior written
                                            approval. The Company has the right to withhold such approval in its sole discretion.

 

	24.	Potential
                                            Conflicts. The Placement Agent, its sub-agents, legal counsel to the Placement Agents,
                                            CKR and/or their respective affiliates, principals, representatives or employees may now
                                            or hereafter own shares of the Company.

 

	25.	Independent
                                            Nature of Each Purchaser’s Obligations and Rights. For avoidance of doubt, the
                                            obligations of the Purchaser under this Agreement are several and not joint with the obligations
                                            of any other Purchaser, and the Purchaser shall not be responsible in any way for the performance
                                            of the obligations of any other Purchaser under any other Subscription Agreement. Nothing
                                            contained herein and no action taken by the Purchaser shall be deemed to constitute the Purchaser
                                            as a partnership, an association, a joint venture, or any other kind of entity, or create
                                            a presumption that the Purchasers are in any way acting in concert or as a group with respect
                                            to such obligations or the transactions contemplated by this Agreement and any other Subscription
                                            Agreements. The Purchaser shall be entitled to independently protect and enforce its rights,
                                            including without limitation the rights arising out of this Agreement, and it shall not be
                                            necessary for any other Purchaser to be joined as an additional party in any proceeding for
                                            such purpose.

 

[Signature
page follows.]

 

    	19

     

    

 

	26.	IN
  WITNESS WHEREOF, the Company has duly executed this Subscription Agreement as of the [____] day of ______, 2018.

 

	 	SHUTTLE
    PHARMACEUTICALS HOLDINGS, INC.

 

	 	By:	
	 	Name:	 
	 	Title:	

 

    	20

     

    

 

FINAL

 

How
to subscribe for Units in the private offering of

Shuttle Pharmaceuticals Holdings, Inc.:

 

		1.	Date
                                            and Fill in the number of Units being purchased and complete and sign the Omnibus
                                            Signature Page.

 

		2.	Initial
                                            the Accredited Investor Certification in the appropriate place or places.

 

		3.	Complete
                                            and sign the Investor Profile.

 

		4.	Complete
                                            and sign the Anti-Money Laundering Information Form.

 

		5.	Fax
                                            or email all forms and then send all signed original documents to:

 

CKR
LAW LLP

1330
Avenue of the Americas

New York, NY 10019

Facsimile
Number: 212.259.8200

Telephone
Number: 212.259.7300

Attn: Megan J. Penick

E-mail
Address: mpenick@ckrlaw.com

 

		6.	If
                                            you are paying the Purchase Price by check, a certified or other bank check for the
                                            exact dollar amount of the Purchase Price for the number of Shares you are purchasing should
                                            be made payable to the order of “CKR Law LLP, as Escrow Agent for Shuttle Pharmaceuticals
                                            Holdings, Inc.” and should be sent directly to CKR Law, LLP, 1330 Avenue of the
                                            Americas, 14th Floor, New York, NY 10019, Attention: Liana Colbourne.

 

Checks
take up to 5 business days to clear. A check must be received by the Escrow Agent at least 6 business days before the closing date.

 

		7.	If
                                            you are paying the Purchase Price by wire transfer, you should send a wire transfer
                                            for the exact dollar amount of the Purchase Price for the number of Shares you are purchasing
                                            according to the following instructions:

 

	 	Bank:	Citibank,
N.A., 666 Fifth Avenue, New York, NY 10103

	 	ABA/Routing
    #:	021000089
	 	Account
    Name:	CKR
    Law LLP Attorney Trust Account
	 	Account
    #:	4987285785
	 	Swift
    Code:	CITIUS33
	 	Reference:	[please
    insert name] – Shuttle Pharmaceuticals Holdings,
    Inc.

 

CKR
Law LLP Accounting Contact:

Liana
Colbourn; telephone: 212-259-7300; lcolbourn@ckrlaw.com

 

Thank
you for your interest,

 

Shuttle
Pharmaceuticals Holdings, Inc.

 

    	 

     

    

 

OMNIBUS
SIGNATURE PAGE TO

SUBSCRIPTION
AGREEMENT AND REGISTRATION RIGHTS AGREEMENT

 

The
undersigned, desiring to: (i) enter into the Subscription Agreement, dated as of _____________ ____,1 2018 (the “Subscription
Agreement”), between the undersigned, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the
“Company”), and the other parties thereto, in or substantially in the form furnished to the undersigned, (ii)
enter into the Registration Rights Agreement (the “Registration Rights Agreement”), among the undersigned,
the Company and the other parties thereto, in or substantially in the form furnished to the undersigned, and (iii) purchase the Shares
of the Company’s securities as set forth in the Subscription Agreement and below, hereby agrees to purchase such Shares from the
Company and further agrees to join the Subscription Agreement and the Registration Rights Agreement as a party thereto, with all the
rights and privileges appertaining thereto, and to be bound in all respects by the terms and conditions thereof. The undersigned specifically
acknowledges having read the representations section in the Subscription Agreement entitled “Representations, Warranties and Agreements
of the Subscriber” and hereby represents that the statements contained therein are complete and accurate with respect to the undersigned
as a Subscriber.

 

IN
WITNESS WHEREOF, the Subscriber hereby executes this Agreement and the Registration Rights Agreement.

 

Dated:__________________,
2018

 

	 	X	$[     ]	 	=	$
	Number
    of Shares	 	Purchase
    Price per Share	 	 	Total
    Purchase Price

 

	SUBSCRIBER
    (individual)	 	SUBSCRIBER
    (entity)

 

		 	 
	Signature	 	Name
    of Entity

 

		 	By:	
	Print
    Name	 		Signature

 

		 	Print
    Name:	 

	Signature
    (if Joint Tenants or Tenants in Common)	 	Title:	

 

	Address
    of Principal Residence:	 	Address of Executive Offices:
		 	
		 	
		 	

 

	Social
    Security Number(s):	 	IRS Tax Identification Number:
	 	 	 

 

	Telephone
    Number:	 	Telephone Number:
	 	 	

 

	Facsimile
    Number:	 	Facsimile Number:
	 	 	 

 

	E-mail
    Address:	 	E-mail Address:
		 	

 

 

 

1
Will reflect the Closing Date. Not to be completed by Purchaser.

 

    	 

     

    

 

Shuttle
Pharmaceuticals Holdings, Inc.

 

ACCREDITED
INVESTOR CERTIFICATION

 

For
Individual Investors Only

(all
Individual Investors must INITIAL where appropriate):

 

	Initial
________     	 	I
    have a net worth of at least US$1 million either individually or through aggregating my individual holdings and those in which I
    have a joint, community property or other similar shared ownership interest with my spouse. (For purposes of calculating your
    net worth under this paragraph, (a) your primary residence shall not be included as an asset; (b) indebtedness secured by
    your primary residence, up to the estimated fair market value of your primary residence at the time of your purchase of the securities,
    shall not be included as a liability (except that if the amount of such indebtedness outstanding at the time of your purchase of
    the securities exceeds the amount outstanding sixty (60) days before such time, other than as a result of the acquisition of your
    primary residence, the amount of such excess shall be included as a liability); and (c) indebtedness that is secured by your primary
    residence in excess of the estimated fair market value of your primary residence at the time of your purchase of the securities shall
    be included as a liability.)
	 	 	 
	Initial ________	 	I
    have had an annual gross income for the past two (2) years of at least US$200,000 (or US$300,000 jointly with my spouse) and expect
    my income (or joint income, as appropriate) to reach the same level in the current year.
	 	 	 
	Initial ________	 	I
    am a director or executive officer of__________.

 

For
Non-Individual Investors (Entities)

(all
Non-Individual Investors must INITIAL where appropriate):

 

	Initial ________	 	The
    investor certifies that it is a partnership, corporation, limited liability company or business trust that is 100% owned by persons
    who meet at least one of the criteria for Individual Investors set forth above (in which case each such person must complete the
    Accreditor Investor Certification for Individuals above as well the remainder of this questionnaire).
	 	 	 
	Initial ________	 	The
    investor certifies that it is a partnership, corporation, limited liability company or business trust that has total assets of at
    least US$5 million and was not formed for the purpose of investing the Company.
	 	 	 
	Initial ________	 	The
    investor certifies that it is an employee benefit plan whose investment decision is made by a plan fiduciary (as defined in ERISA
    §3(21)) that is a bank, savings and loan association, insurance company or registered investment advisor.
	 	 	 
	Initial ________	 	The
    investor certifies that it is an employee benefit plan whose total assets exceed US$5,000,000 as of the date of this Agreement.
	 	 	 
	Initial ________	 	The
    undersigned certifies that it is a self-directed employee benefit plan whose investment decisions are made solely by persons who
    meet at least one of the criteria for Individual Investors.
	 	 	 
	Initial ________	 	The
    investor certifies that it is a U.S. bank, U.S. savings and loan association or other similar U.S. institution acting in its individual
    or fiduciary capacity.
	 	 	 
	Initial ________	 	The
    undersigned certifies that it is a broker-dealer registered pursuant to §15 of the Securities Exchange Act of 1934.
	 	 	 
	Initial ________	 	The
    investor certifies that it is an organization described in §501(c)(3) of the Internal Revenue Code with total assets exceeding
    US$5,000,000 and not formed for the specific purpose of investing in the Company.
	 	 	 
	Initial ________	 	The
    investor certifies that it is a trust with total assets of at least US$5,000,000, not formed for the specific purpose of investing
    in the Company, and whose purchase is directed by a person with such knowledge and experience in financial and business matters that
    such person is capable of evaluating the merits and risks of the prospective investment.
	 	 	 
	Initial ________	 	The
    investor certifies that it is a plan established and maintained by a state or its political subdivisions, or any agency or instrumentality
    thereof, for the benefit of its employees, and which has total assets in excess of US$5,000,000.
	 	 	 
	Initial ________	 	The
    investor certifies that it is an insurance company as defined in §2(13) of the Securities Act of 1933, or a registered investment
    company.

 

    	 

     

    

 

Shuttle
Pharmaceuticals Holdings, Inc.

 

Investor
Profile

(Must
be completed by Investor)

 

Section
A - Personal Investor Information

 

Investor
Name(s): _________________________________________________________________________________

 

Individual
executing Profile or Trustee: _________________________________________________________________

 

Social
Security Numbers / Federal I.D. Number: ___________________________________________________________

 

Date
of Birth:___________________________                      Marital
Status: _______________________________

 

Joint
Party Date of
Birth:                      ________________                  Investment
Experience (Years): ____________________

 

Annual
Income: _________________________                                Liquid
Net Worth: ______________________________

 

Net
Worth*: ___________________________

 

Tax
Bracket:                    ________ 15%
or below                    ________
25% - 27.5%              ________ Over 27.5%

 

Home
Street Address: ______________________________________________________________________________

 

Home
City, State & Zip Code: ________________________________________________________________________

 

Home
Phone: _____________________     Home Fax: _____________________    Home Email: _____________________

 

Employer:  _______________________________________________________________________________________

 

Employer
Street Address: ___________________________________________________________________________

 

Employer
City, State & Zip Code: ______________________________________________________________________

 

Bus.
Phone: ____________________   Bus. Fax: _____________________   Bus. Email: __________________________

 

Type
of Business: _________________________________________________________________________________

 

Outside
Broker/Dealer: ______________________________________________________________________________

 

Section
B – Certificate Delivery Instructions

 

____
Please deliver certificate to the Employer Address listed in Section A.

____
Please deliver certificate to the Home Address listed in Section A.

____ Please
deliver certificate to the following address: _____________________________________________________

 

Section
C – Form of Payment – Check or Wire Transfer

 

____
Check payable to [Delaware Trust Company, as Escrow Agent for Shuttle Pharmaceuticals Holdings, Inc., ACCT#
[__________]

____Wire
funds from my outside account according to Section 2(b) of the Subscription Agreement.

____The
funds for this investment are rolled over, tax deferred from ___________within the allowed 60-day window.

 

Please
check if you are a FINRA member or Affiliate of a FINRA member firm: _____

 

	 	 	 
	Investor
    Signature	 	Date

  

*
For purposes of calculating your net worth in this form, (a) your primary residence shall not be included as an asset; (b) indebtedness
secured by your primary residence, up to the estimated fair market value of your primary residence at the time of your purchase of the
securities, shall not be included as a liability (except that if the amount of such indebtedness outstanding at the time of your purchase
of the securities exceeds the amount outstanding sixty (60) days before such time, other than as a result of the acquisition of your
primary residence, the amount of such excess shall be included as a liability); and (c) indebtedness that is secured by your primary
residence in excess of the estimated fair market value of your primary residence at the time of your purchase of the securities shall
be included as a liability.

 

    	 

     

    

 

ANTI
MONEY LAUNDERING REQUIREMENTS

 

The
USA PATRIOT Act

 

The
USA PATRIOT Act is designed to detect, deter, and punish terrorists in the United States and abroad. The Act imposes new anti-money laundering
requirements on brokerage firms and financial institutions. Since April 24, 2002 all brokerage firms have been required to have new,
comprehensive anti-money laundering programs.

 

To
help you understand these efforts, we want to provide you with some information about money laundering and our steps to implement the
USA PATRIOT Act.

 

What
is money laundering?

 

Money
laundering is the process of disguising illegally obtained money so that the funds appear to come from legitimate sources or activities.
Money laundering occurs in connection with a wide variety of crimes, including illegal arms sales, drug trafficking, robbery, fraud,
racketeering, and terrorism.

 

How
big is the problem and why is it important?

 

The
use of the U.S. financial system by criminals to facilitate terrorism or other crimes could well taint our financial markets. According
to the U.S. State Department, one recent estimate puts the amount of worldwide money laundering activity at $1 trillion a year.

 

What
are we required to do to eliminate money laundering?

 

Under
rules required by the USA PATRIOT Act, our anti-money laundering program must designate a special compliance officer, set up employee
training, conduct independent audits, and establish policies and procedures to detect and report suspicious transaction and ensure compliance
with such laws. As part of our required program, we may ask you to provide various identification documents or other information. Until
you provide the information or documents we need, we may not be able to effect any transactions for you.

 

    	 

     

    

 

ANTI-MONEY
LAUNDERING INFORMATION FORM

The
following is required in accordance with the AML provision of the USA PATRIOT ACT.

(Please
fill out and return with requested documentation.)

 

INVESTOR
NAME:        _________________________________________________________________________

 

LEGAL
ADDRESS:        _________________________________________________________________________

 

                                           _________________________________________________________________________

 

SSN#
or TAX ID# OF INVESTOR: _______________________________________________________________

 

YEARLY
INCOME: ___________________________________________________________________________

 

NET
WORTH:   ______________________________________________________________________________

 

*
For purposes of calculating your net worth in this form, (a) your primary residence shall not be included as an asset; (b) indebtedness
secured by your primary residence, up to the estimated fair market value of your primary residence at the time of your purchase of the
securities, shall not be included as a liability (except that if the amount of such indebtedness outstanding at the time of your purchase
of the securities exceeds the amount outstanding sixty (60) days before such time, other than as a result of the acquisition of your
primary residence, the amount of such excess shall be included as a liability); and (c) indebtedness that is secured by your primary
residence in excess of the estimated fair market value of your primary residence at the time of your purchase of the securities shall
be included as a liability.

 

INVESTMENT
OBJECTIVE(S) (FOR ALL INVESTORS): __________________________________________________

 

ADDRESS
OF BUSINESS OR OF EMPLOYER: __________________________________________________________

 

                                                                                      __________________________________________________________

 

FOR
INVESTORS WHO ARE INDIVIDUALS: AGE: ______________________________________________________

 

FOR
INVESTORS WHO ARE INDIVIDUALS: OCCUPATION: ______________________________________________

 

FOR
INVESTORS WHO ARE ENTITIES: TYPE OF BUSINESS: _____________________________________________

 

IDENTIFICATION
& DOCUMENTATION AND SOURCE OF FUNDS:

 

	1.	Please
                                            submit a copy of non-expired identification for the authorized signatory(ies) on the investment
                                            documents, showing name, date of birth, address and signature. The address shown on the
                                            identification document MUST match the Investor’s address shown on the Investor Signature
                                            Page.

 

	 	Current
    Driver’s License	or	Valid
    Passport	or	Identity
    Card
	 	 	 	(Circle
    one or more)	 	 

 

	2.	If
                                            the Investor is a corporation, limited liability company, trust or other type of entity,
                                            please submit the following requisite documents: (i) Certificate of Incorporation, By-Laws,
                                            Certificate of Formation, Operating Agreement, Trust or other similar documents for the type
                                            of entity; and (ii) Corporate Resolution or power of attorney or other similar document granting
                                            authority to signatory(ies) and designating that they are permitted to make the proposed
                                            investment.

 

	3.	Please
                                            advise where the funds were derived from to make the proposed investment:

 

	 	Investments	Savings	Proceeds
    of Sale	Other
    _____________
	 	 	 	(Circle
    one or more)	 

 

Signature: __________________________________________

Print
Name: _________________________________________

Title
(if applicable): ___________________________________

Date:
______________________________________________

 

    	 

     

    

 

Schedule
4a

 

Subsidiaries

 

Shuttle
Pharmaceuticals, Inc., a Maryland corporation

 

    	 

     

    

 

EXHIBIT
A

Form
of Warrant

 

    	 

     

    

 

FINAL

 

NEITHER
THIS WARRANT NOR THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS, AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED,
SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE SECURITIES
ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR (2) AN EXEMPTION FROM SUCH REGISTRATION EXISTS AND THE COMPANY RECEIVES AN OPINION OF
COUNSEL, WHICH COUNSEL AND OPINION ARE REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED
OR TRANSFERRED IN THE MANNER CONTEMPLATED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR APPLICABLE STATE SECURITIES
LAWS. HEDGING TRANSACTIONS INVOLVING THESE SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT.

 

	WARRANT
    NO. [________]	NUMBER
    OF SHARES: [_________]
	DATE
    OF ISSUANCE: [___], 2018	(subject
    to adjustment hereunder)
	EXPIRATION
    DATE: [___], 2021	 

 

CALLABLE
WARRANT TO PURCHASE SHARES

OF
COMMON STOCK OF

 

SHUTTLE
PHARMACEUTICALS HOLDINGS, INC.

 

This
Warrant is issued to [____________], or its registered assigns (including any successors or assigns, the “Warrantholder”),
in connection with that certain Subscription Agreement, dated as of [___], 2018, by and among Shuttle Pharmaceuticals, Inc., a Delaware
corporation (the “Company”), and each of those Purchaser party thereto (the “Subscription Agreement”).

 

		1.	EXERCISE
                                            OF WARRANT.

 

(a)
Number and Exercise Price of Warrant Shares; Expiration Date. Subject to the terms and conditions set forth herein and set forth
in the Subscription Agreement, the Warrantholder is entitled to purchase from the Company up to [____________] shares (the “Warrant
Shares”) of the Company’s Common Stock, $0.00001 par value per share (the “Common Stock”), at a purchase
price of $[     ] per share (as adjusted from time to time pursuant to the provisions of this Warrant) (the “Exercise Price”),
on or before 5:00 p.m. New York City time on [__], 2021 (the “Expiration Date”) (subject to earlier
termination of this Warrant as set forth herein).

 

(b) Method
of Exercise. While this Warrant remains outstanding and exercisable in accordance with Section 1(a) above, the
Warrantholder may exercise this Warrant in accordance with Section 6 herein, by wire transfer to the Company or
cashier’s check drawn on a United States bank made payable to the order of the Company.

 

(c) Return
of Warrant. Notwithstanding anything herein to the contrary, the Warrantholder shall not be required to physically surrender
this Warrant to the Company until the Warrantholder has purchased all of the Warrant Shares available hereunder and the Warrant has
been exercised in full, in which case, the Warrantholder shall surrender this Warrant to the Company for cancellation within three
(3) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting
in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the
outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased.
The Warrantholder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such
purchases.

 

    	 

     

    

 

“Trading
Day” shall mean (i) if the Common Stock is listed for trading on a national securities exchange, a day on which such exchange
is open for business; or (ii) if the Common Stock is quoted on OTC Markets, a day on which trades may be effected through such system;
or (iii) if neither (i) nor (ii) above is applicable, a day other than a Saturday, Sunday or other day on which banks in the State of
New York are required or authorized to be closed.

 

“OTC
Markets” shall mean either OTC QX, OTC QB or OTC Pink tier of the OTC Markets Group, Inc.

 

		2.	CALL
                                            OF WARRANT.

 

If
at any time after the date of the issuance of this Warrant (a) the Common Stock is listed on a Qualified Exchange, (b) the Warrant Shares
are either (i) registered under the Securities Act for resale pursuant to an effective registration statement naming the Warrantholder
as a selling stockholder thereunder or (ii) freely transferable without volume restrictions pursuant to Rule 144 promulgated under the
Securities Act, as determined by counsel to the Company pursuant to a written opinion letter addressed and in form and substance acceptable
to the Holder, the Company and the transfer agent for the Common Stock, and (c) the VWAP of the Common Stock for a period of twenty (20)
consecutive Trading Days exceeds 150% of the IPO Price or, if a Qualified IPO has not then occurred, $20.82 (subject to adjustment proportionally
for any subdivision, split-up or combination of the Common Stock), then the Company shall have the right (but not the obligation) within
twenty (20) Trading Days after the end of any such period of twenty (20) consecutive Trading Days, upon written notice to the Warrantholder
(the “Call Notice”), to call for the exercise of this Warrant. The Call Notice shall be deemed effective upon mailing
to the Warrantholder’s address of record, and the time of mailing is the “Effective Date of the Notice.” The
Call Notice shall state the exercise period and a cancellation date not less than twenty (20) Trading Days from the Effective Date of
the Notice (the “Cancellation Date”).

 

“Qualified
Exchange” shall mean the New York Stock Exchange, NYSE American, Nasdaq Global Select Market, Nasdaq Global Market or Nasdaq
Capital Market.

 

“Qualified
IPO” shall mean the closing of the sale of shares of Common Stock to the public at a price per share of at least $13.88 (subject
to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect
to the Common Stock), in a firm commitment underwritten public offering (the “Offering”)_pursuant to an effective
registration statement under the Securities Act, resulting in gross proceeds (before underwriters’ discount, commissions and expenses)
to the Company of at least $[___________]1.

 

“VWAP”
for any Trading Day shall mean the volume-weighted average price for the Common Stock on such Trading Day on the Qualified Exchange
during regular trading hours, as reported by Bloomberg L.P., or, if no volume-weighted average price is reported for the Common
Stock by Bloomberg
L.P. for such Trading Day, the average of the highest closing bid price and the lowest closing ask price for the Common Stock of any
of the market makers for the Common Stock as reported by OTC Markets Group, Inc.

 

 

1
The difference between $15,000,000 and the gross proceeds received from the Company in the Offering of units consisting of the
Company’s Series A Convertible Preferred Stock and Warrants of like tenor with this Warrant.

 

    	 

     

    

 

“IPO
Price” means the gross public offering price per share of the Qualified IPO (before deducting underwriters’ discount,
commissions and expenses).

 

The
Warrantholder may exercise this Warrant (in whole or in part) between the Effective Date of the Notice and the Cancellation Date, such
exercise being effective if done in accordance with Sections 1(c) and 6 hereof, and if the Exercise Price for the number of Warrant Shares
to be issued pursuant to such Exercise is actually received by the Company no later than 5:00 PM New York, NY, time on the Cancellation
Date.

 

If
Holder does not wish to exercise this Warrant, the Holder should mail this Warrant to the Company at its principal office after receiving
the Call Notice.

 

If
the Call Notice shall have been so mailed, then, on and after such Cancellation Date, notwithstanding that this Warrant shall not have
been surrendered for redemption, the obligations evidenced by this Warrant not effectively exercised shall be deemed void and no longer
outstanding, and all rights with respect hereto shall forthwith cease and terminate.

 

		3.	CERTAIN
                                            ADJUSTMENTS.

 

(a) Adjustment
of Number of Warrant Shares and Exercise Price. The number and kind of Warrant Shares purchasable upon exercise of this Warrant
and the Exercise Price shall be subject to adjustment from time to time as follows:

 

(1) Subdivisions,
Combinations and Other Issuances. If the Company shall at any time after the Date of Issuance but prior to the Expiration Date
subdivide its shares of capital stock of the same class as the Warrant Shares, by split-up or otherwise, or combine such shares of
capital stock, or issue additional shares of capital stock as a dividend with respect to any shares of such capital stock, the
number of Warrant Shares issuable on the exercise of this Warrant shall forthwith be proportionately increased in the case of a
subdivision or stock dividend, or proportionately decreased in the case of a combination. Appropriate adjustments shall also be made
to the Exercise Price payable per share, but the aggregate Exercise Price payable for the total number of Warrant Shares purchasable
under this Warrant (as adjusted) shall remain the same. Any adjustment under this Section 3(a)(1) shall become effective at
the close of business on the date the subdivision or combination becomes effective, or as of the record date of such dividend, or in
the event that no record date is fixed, upon the making of such dividend.

 

(2) Reclassification,
Reorganizations and Consolidation. In case of any reclassification, capital reorganization or change in the capital stock of the
Company (other than as a result of a subdivision, combination or stock dividend provided for in Section 3(a)(1) above) that
occurs after the Date of Issuance, then, as a condition of such reclassification, reorganization or change, lawful provision shall
be made, and duly executed documents evidencing the same from the Company or its successor shall be delivered to the Warrantholder,
so that the Warrantholder shall thereafter have the right at any time prior to the expiration of this Warrant to purchase, at a
total price equal to that payable upon the exercise of this Warrant, the kind and amount of shares of stock and/or other securities
or property (including, if applicable, cash) receivable in connection with such reclassification, reorganization or change by a
holder of the same number and type of securities as were purchasable as Warrant Shares by the Warrantholder immediately prior to
such reclassification, reorganization or change. In any such case appropriate provisions shall be made with respect to the rights
and interest of the Warrantholder so that the provisions hereof shall thereafter be applicable with respect to any shares of stock
or other securities or property deliverable upon exercise hereof, and appropriate adjustments shall be made to the Exercise Price
payable hereunder, provided the aggregate Exercise Price shall remain the same (and, for the avoidance of doubt, this Warrant shall
be exclusively exercisable for such shares of stock and/or other securities or property from and after the consummation of such
reclassification or other change in the capital stock of the Company).

 

    	-2-

     

    

 

 (b) Notice to Warrantholder. If, while this Warrant is outstanding, the Company (i) declares a dividend or any other distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any subsidiary, (ii) authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Change of Control or (iii) authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company, then the Company shall deliver to the Warrantholder a notice of such transaction at least ten (10) business days prior to the applicable record or effective date on which a person would need to hold Common Stock in order to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice.

 

(c) Calculations.
All calculations under this Section 3 shall be made to the nearest cent or the nearest whole share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum
of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

 (d) Treatment of Warrant upon a Change of Control.

 

(1)
If, at any time while this Warrant is outstanding, the Company consummates a Change of Control, then a holder shall have the right
thereafter to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been
entitled to receive upon the occurrence of such Change of Control if it had been, immediately prior to such Change of Control, a
holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant (the “Alternate
Consideration”). The Company shall not effect any such Change of Control unless prior to or simultaneously with the
consummation thereof, any successor to the Company, surviving entity or the corporation purchasing or otherwise acquiring such
assets or other appropriate corporation or entity shall assume the obligation to deliver to the holder, such Alternate Consideration
as, in accordance with the foregoing provisions, the holder may be entitled to purchase, and the other obligations under this
Warrant.

 

(2)
As used in this Warrant, a “Change of Control” shall mean (i) a merger or consolidation of the Company with
another corporation (other than a merger effected exclusively for the purpose of changing the domicile of the Company), (ii) the
sale, assignment, transfer, conveyance or other disposal of all or substantially all of the properties or assets or all or a
majority of the outstanding voting shares of capital stock of the Company, (iii) a purchase, tender or exchange offer accepted by
the holders of a majority of the outstanding voting shares of capital stock of the Company, or (iv) a “person” or
“group” (as these terms are used for purposes of Section 13(d) and 14(d) of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”)) is or shall become the “beneficial owner” (as defined in Rule 13d-3
under the Exchange Act), directly or indirectly at least a majority of the voting power of the capital stock of the
Company.

 

4.
NO FRACTIONAL SHARES. No fractional Warrant Shares or scrip representing fractional shares will be issued upon exercise of this
Warrant. In lieu of any fractional shares which would otherwise be issuable, the Company shall pay cash equal to the product of such
fraction multiplied by the Fair Market Value of one Warrant Share.

 

    	-3-

     

    

 

The
“Fair Market Value” of one share of Common Stock shall mean (x) the last reported sale price and, if there are no
sales, the last reported bid price, of the Common Stock on the business day prior to the date of exercise on the Trading Market on which
the Common Stock is then listed or quoted as reported by Bloomberg Financial Markets (or a comparable reporting service of national reputation
selected by the Company and reasonably acceptable to the holder if Bloomberg Financial Markets is not then reporting sales prices of
the Common Stock) (collectively, “Bloomberg”), (y) if the foregoing does not apply, the last sales price of the Common
Stock in the over-the-counter market on the pink sheets or bulletin board for such security as reported by Bloomberg, and, if there are
no sales, the last reported bid price of the Common Stock as reported by Bloomberg or, (z) if fair market value cannot be calculated
as of such date on either of the foregoing bases, the price determined in good faith by the Company’s Board of Directors.

 

“Trading
Market” shall mean any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the
date in question: the NYSE MKT, the NASDAQ Capital Market, the NASDAQ Global Market, the NASDAQ Global Select Market, the New York Stock
Exchange or the OTC Markets (or any successors to any of the foregoing).

 

5.
NO STOCKHOLDER RIGHTS. Until the exercise of this Warrant or any portion of this Warrant, the Warrantholder shall not have, nor
exercise, any rights as a stockholder of the Company (including without limitation the right to notification of stockholder meetings
or the right to receive any notice or other communication concerning the business and affairs of the Company) except as provided in
Section 9 below.

 

		6.	MECHANICS
                                            OF EXERCISE.

 

(a) Delivery
of Warrant Shares Upon Exercise. This Warrant may be exercised by the holder hereof, in whole or in part, by delivering to the
Company (or such other office or agency of the Company as it may designate by notice in writing to the registered Warrantholder at
the address of the Warrantholder appearing on the books of the Company) of a duly executed copy of the Notice of Exercise in the
form attached hereto as Exhibit A by facsimile or e-mail attachment and paying the Exercise Price then in effect with respect
to the number of Warrant Shares as to which the Warrant is being exercised. This Warrant shall be deemed to have been exercised
immediately prior to the close of business on the date of the delivery to the Company of the Notice of Exercise as provided above,
and the person entitled to receive the Warrant Shares issuable upon such exercise shall be treated for all purposes as the holder of
such shares of record as of the close of business on such date. Warrant Shares purchased hereunder shall be transmitted by the
Company’s transfer agent to the holder by crediting the account of the holder’s prime broker with The Depository Trust
Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in
such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale
of the Warrant Shares by the holder or (B) the shares are eligible for resale by the holder without volume or manner-of-sale
limitations pursuant to Rule 144, and otherwise by physical delivery to the address specified by the holder in the Notice of
Exercise by the end of the day on the date that is three (3) Trading Days from the delivery to the Company of the Notice of Exercise
and payment of the aggregate Exercise Price. The Warrant Shares shall be deemed to have been issued, and the holder or any other
person so designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of
the date the Warrant has been exercised, with payment to the Company of the Exercise Price and all taxes required to be paid by the
holder, if any, prior to the issuance of such shares, having been paid.

 

    	-4-

     

    

 

(b) Rescission
Rights. If the Company fails to cause the transfer agent to transmit to the Warrantholder the Warrant Shares pursuant to Section
6(a) by the Warrant Share Delivery Date, then the Warrantholder will have the right to rescind such exercise.

 

7.
CERTIFICATE OF ADJUSTMENT. Whenever the Exercise Price or number or type of securities issuable upon exercise of this Warrant is
adjusted, as herein provided, the Company shall, at its expense, promptly deliver to the Warrantholder a certificate of an officer
of the Company setting forth the nature of such adjustment and showing in detail the facts upon which such adjustment is
based.

 

		8.	COMPLIANCE
                                            WITH SECURITIES LAWS.

 

(a)
The Warrantholder understands that this Warrant and the Warrant Shares are characterized as “restricted securities”
under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public
offering and that under such laws and applicable regulations this Warrant and the Warrant Shares may be resold without registration
under the Securities Act only in certain limited circumstances. In this connection, the Warrantholder represents that it is familiar
with Rule 144 under the Securities Act, as presently in effect, and understands the resale limitations imposed thereby and by the
Securities Act.

 

(b)
Prior and as a condition to the sale or transfer of the Warrant Shares issuable upon exercise of this Warrant, the Warrantholder
shall furnish to the Company such certificates, representations, agreements and other information, including an opinion of counsel,
as the Company or the Company’s transfer agent reasonably may require to confirm that such sale or transfer is being made
pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, unless such
Warrant Shares are being sold or transferred pursuant to an effective registration statement.

 

(c)
The Warrantholder acknowledges that the Company may place a restrictive legend on the Warrant Shares issuable upon exercise of this
Warrant in order to comply with applicable securities laws, in substantially the following form and substance:

 

THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), OR ANY STATE SECURITIES LAWS, AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED
OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE SECURITIES ACT AND ANY APPLICABLE
STATE SECURITIES LAWS, OR (2) AN EXEMPTION FROM SUCH REGISTRATION EXISTS AND THE COMPANY RECEIVES AN OPINION OF COUNSEL, WHICH COUNSEL
AND OPINION ARE REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR TRANSFERRED IN
THE MANNER CONTEMPLATED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR APPLICABLE STATE SECURITIES LAWS. HEDGING
TRANSACTIONS INVOLVING THESE SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH.

 

9.
REPLACEMENT OF WARRANTS. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation
of this Warrant and, in the case of any such loss, theft or destruction of this Warrant, on delivery of an indemnity agreement
reasonably satisfactory in form and amount to the Company or, in the case of any such mutilation, on surrender and cancellation of
such Warrant, the Company at its expense will execute and deliver, in lieu thereof, a new Warrant of like tenor.

 

    	-5-

     

    

 

10.
NO IMPAIRMENT. Except to the extent as may be waived by the holder of this Warrant, the Company will not, by amendment of its
charter or through a Change of Control, dissolution, sale of assets or any other voluntary action, avoid or seek to avoid the
observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all
such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the
Warrantholder against impairment.

 

11.
TRADING DAYS. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein
shall be other than a day on which the Common Stock is traded on the Trading Market, then such action may be taken or such right may
be exercised on the next succeeding day on which the Common Stock is so traded.

 

		12.	TRANSFERS;
                                            EXCHANGES.

 

(a)
Except as provided hereinafter in this Section, neither this Warrant nor any right or obligation hereunder may be assigned in whole
or in part by the Warrantholder. Subject to compliance with applicable federal and state securities laws and Section 8
hereof, this Warrant may be transferred by the Warrantholder in a Permitted Transfer (as defined below) with respect to any or all
of the Warrant Shares purchasable hereunder (a “Permitted Transfer”). For a transfer of this Warrant as an
entirety by the Warrantholder, upon surrender of this Warrant to the Company, together with the Notice of Assignment in the form
attached hereto as Exhibit B duly completed and executed on behalf of the Warrantholder, the Company shall issue a new
Warrant of the same denomination to the assignee. For a transfer of this Warrant with respect to a portion of the Warrant Shares
purchasable hereunder, upon surrender of this Warrant to the Company, together with the Notice of Assignment in the form attached
hereto as Exhibit B duly completed and executed on behalf of the Warrantholder, the Company shall issue a new Warrant to the
assignee, in such denomination as shall be requested by the Warrantholder, and shall issue to the Warrantholder a new Warrant
covering the number of shares in respect of which this Warrant shall not have been transferred.

 

“Permitted
Transfer” shall mean:

 

(i)
if the Warrantholder is a natural person, any transfers made by the Warrantholder (A) to any member of the Immediate Family of the
Warrantholder or to a trust the direct or indirect beneficiaries of which are exclusively the Warrantholder or members of the
Warrantholder’s Immediate Family, or (B) by bona fide gift, will or intestacy to members of the Warrantholder’s
Immediate Family;

 

 (ii) any transfer to a charitable organization not for value;

 

(iii)
if the Warrantholder is a corporation, partnership, limited liability company or other business entity, any transfer made by the
Warrantholder:

 

(A)
in connection with the sale or other bona fide transfer in a single transaction of all or substantially all of the
Warrantholder’s capital stock, partnership interests, membership interests or other similar equity interests, as the case may
be, or all or substantially all of the Warrantholder’s assets, in any such case not undertaken for the purpose of avoiding the
restrictions imposed by this Agreement,

 

    	-6-

     

    

 

(B)
to another corporation, partnership, limited liability company or other business entity so long as the transferee is an Affiliate of
the Warrantholder,

 

 (C) to any Affiliate of the Warrantholder, or

 

(D)
to any investment fund or other entity that controls or manages the Warrantholder (including, for the avoidance of doubt, a fund
managed by the same manager or managing member or general partner or management company or by an entity controlling, controlled by,
or under common control with such manager or managing member or general partner or management company as the Warrantholder) if such
transfer is not for value;

 

(iv)
if the Warrantholder is a trust, any transfer to a trustor or beneficiary of the trust if such transfer is not for value;
or

 

(v)
any transfer pursuant to a court order or by operation of law, including pursuant to a domestic order or a negotiated divorce
settlement.

 

“Immediate
Family” means mother, father, son, daughter or sibling or relation by domestic partnership, marriage or adoption.

 

“Affiliate”
means, with respect to any person, any other person that, directly or indirectly through one or more intermediaries, controls, is controlled
by or is under common control with such person, and any officers, employees or partners of the Warrantholder.

 

(b)
Upon any Permitted Transfer, this Warrant is exchangeable, without expense, at the option of the Warrantholder, upon presentation
and surrender hereof to the Company for other warrants of different denominations entitling the holder thereof to purchase in the
aggregate the same number of shares of Common Stock purchasable hereunder. This Warrant may be divided or combined with other
warrants that carry the same rights upon presentation hereof at the principal office of the Company together with a written notice
specifying the denominations in which new warrants are to be issued to the Warrantholder and signed by the Warrantholder hereof. The
term “Warrants” as used herein includes any warrants into which this Warrant may be divided or
exchanged.

 

13.
AUTHORIZED SHARES. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and
unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any
purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority
to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under
this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued
as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which
the Common Stock may be quoted or listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the
purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for
such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all
taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer
occurring contemporaneously with such issue).

 

14.
NO STOCK RIGHTS. No holder of this Warrant, as such, shall be entitled to vote or be deemed the holder of any other securities of
the Company that may at any time be issuable on the exercise hereof, nor shall anything contained herein be construed to confer upon
the holder of this Warrant, as such, the rights of a stockholder of the Company or the right to vote for the election of directors
or upon any matter submitted to stockholders at any meeting thereof, or give or withhold consent to any corporate action or to
receive notice of meetings or other actions affecting stockholders (except as provided herein), or to receive dividends or
subscription rights or otherwise (except as provided herein).

 

    	-7-

     

    

 

 

MISCELLANEOUS.

 

(a)
This Agreement shall be governed by and construed in accordance with the laws of the United States of America and the State of New York,
both substantive and remedial, without regard to New York conflicts of law principles. Any judicial proceeding brought under this Agreement
or any dispute arising out of this Agreement or any matter related hereto shall be brought in the courts of the State of New York, New
York County, or in the United States District Court for the Southern District of New York.

 

(b)
Except as otherwise provided herein, any notice, consents, waivers or other communication required or permitted to be given
hereunder shall be in writing and will be deemed to have been delivered: (i) upon receipt, when personally delivered; (ii) upon
receipt when sent by certified mail, return receipt requested, postage prepaid; (iii) upon receipt, when sent by facsimile (provided
confirmation of transmission is mechanically or electronically generated and kept on file by the sending party; (iv) when sent, if
by e-mail, (provided that such sent e-mail is kept on file (whether electronically or otherwise) by the sending party and the
sending party does not receive an automatically generated message from the recipient’s e-mail server that such e-mail could
not be delivered to such recipient); or (v) one (1) Business Day after deposit with an overnight courier service with next day
delivery specified, in each case, properly addressed to the party to receive the same. The addresses, facsimile numbers and email
addresses for such communications shall be:

 

(i)
if to the Company, at

 

Shuttle
Pharmaceuticals Holdings, Inc.

One Research Court, Suite 450

Rockville, MD 20850

Attn:
Chief Financial Officer

Email:
anatoly.dritschilo@shuttlepharma.org

 

with
copies (which shall not constitute notice) to:

 

CKR
Law LLP

1330
Avenue of the Americas

New York, New York 10019

Attention:
Jeffrey A. Rinde, Managing Partner

Facsimile: +1-212-259-8200

E-mail:
jar@ckrlaw.com; and

 

(ii)
if to the Warrantholder, at such address or addresses (including copies to counsel) as may have been furnished by the Warrantholder to
the Company in writing.

 

(c)
The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provisions.

 

[Signature
Page Follows]

 

    	-8-

    	 

    

 

IN
WITNESS WHEREOF, this Common Stock Purchase Warrant is issued effective as of the date first set forth above.

 

	 	Shuttle Pharmaceuticals Holdings,
Inc.
	 	 	 
	 	By:	
	 	Name:
    	Anatoly
    Dritschilo
	 	Title:	Chief
    Executive Officer

 

    	 

    	 

    

 

EXHIBIT
A

 

NOTICE
OF EXERCISE

(To
be signed only upon exercise of Warrant)

 

To:
Shuttle Pharmaceuticals Holdings, Inc.

 

The
undersigned, the Warrantholder of the attached Warrant, hereby irrevocably elects to exercise the purchase right represented by such
Warrant for, and to purchase thereunder, ________________ ( ___) shares of Common Stock of Shuttle Pharmaceuticals Holdings,
Inc. and (complete)

 

herewith
makes payment of __________________________ Dollars ($________ ) thereof.

 

The
undersigned requests that the certificates or book entry position evidencing the shares to be acquired pursuant to such exercise be issued
in the name of, and delivered to

_________________________________________________________________________________, whose address is

______________________________________________________________________________________________

 ______________________________________________________________________________________________ .

 

By
its signature below the undersigned hereby represents and warrants that it is an “accredited investor” as defined in Rule
501(a) of Regulation D promulgated under the Securities Act of 1933, as amended, and agrees to be bound by the terms and conditions of
the attached Warrant as of the date hereof, including Section 8 thereof.

 

	DATED:__________________________________	 

 

	 	(Signature
    must conform in all

    respects
    to name of the Warrantholder

    as
    specified on the face of the Warrant)

	 	 
	 	 
	 	[Name
    of Warrantholder]
	 	Address:
________________________________________    
	 	 
	 	 

 

    	 

    	 

    

 

EXHIBIT
B

 

NOTICE
OF ASSIGNMENT FORM

 

FOR
VALUE RECEIVED, [_____] (the “Assignor”) hereby sells, assigns and transfers all of the rights of the undersigned Assignor
under the attached Warrant with respect to the number of shares of common stock of Shuttle Pharmaceuticals Holdings, Inc. (the
“Company”) covered thereby set forth below, to the following “Assignee” and, in connection with
such transfer, represents and warrants to the Company that the transfer is in compliance with Section 8 of the Warrant and applicable
federal and state securities laws:

 

	NAME
    OF ASSIGNEE	 	ADDRESS/FAX
    NUMBER
	 	 	 
	Number
of shares:_________________________________
	 	 
	Dated:
    _________________________________________	 	Signature:_______________________________________

    

	 	 	Witness:
_______________________________________    

 

ASSIGNEE
ACKNOWLEDGMENT

 

The
undersigned Assignee acknowledges that it has reviewed the attached Warrant and by its signature below it hereby represents and warrants
that it is an “accredited investor” as defined in Rule 501(a) of Regulation D promulgated under the Securities Act of 1933,
as amended, and agrees to be bound by the terms and conditions of the Warrant as of the date hereof, including Section 8 thereof.

 

	 	Signature: 	 
	 	 	 
	 	By:	 
	 	Its:	 

 

	Address:	 
	 	 
	 	 
	 	 

 

    	 

    	 

    

 

EXHIBIT
B

 

Form
of Certificate of Designations

 

    	 

    	 

    

 

FINAL

 

CERTIFICATE
OF DESIGNATIONS,

 

PREFERENCES AND RIGHTS

 

of

 

SERIES
A CONVERTIBLE PREFERRED STOCK

 

of

 

SHUTTLE
PHARMACEUTICALS HOLDINGS, INC.

 

Shuttle
Pharmaceuticals Holdings, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”),
hereby certifies that the Board of Directors of the Corporation (the “Board of Directors” or the “Board”),
pursuant to authority of the Board of Directors as required by applicable law, and in accordance with the provisions of its certificate
of incorporation and by-laws, has authorized and hereby authorizes a series of the Corporation’s previously authorized Preferred
Stock, par value $0.0001 per share (the “Preferred Stock”), and hereby states the designation and number of shares,
and fixes the voting powers, designations, preferences, limitations, restrictions and relative rights thereof, as follows:

 

Capitalized
terms used and not otherwise immediately defined are defined in Section 10 below.

 

1.
Designation and Amount. The series of Preferred Stock shall be designated as the “8.5% Series A Convertible Preferred Stock”
(the “Series A Preferred Stock”) and the number of shares so designated shall be 10,000.

 

2.
Stated Value; Dividends.

 

a.
Par Value and Stated Value. The par value of each issued share of Series A Preferred Stock shall be $0.00001 per share, and the
stated value of each issued share of Series A Preferred Stock shall be deemed to be $1,000 (the “Stated Value”).

 

b.
Dividends. Before any dividends shall be paid or set aside for payment on any Junior Security of the Corporation, each Holder
of the Series A Preferred Stock shall be entitled to receive dividends, in the manner provided herein, payable on the Stated Value of
the Series A Preferred Stock at a rate of 8.5% per annum, which shall be cumulative and be due and payable, at the Company’s option,
in cash or in shares of Common Stock, or a combination thereof, on the Conversion Date (as defined below) or in cash on the Redemption
Date (as defined below), in each case as provided below (the applicable date of payment, a “Dividend Date”). Such
dividends shall accrue from the date of issue of each share of Series A Preferred Stock, whether or not declared, through the Dividend
Date. If a Dividend Date is not a business day, then the dividend shall be due and payable on the business day immediately following
such Dividend Date.

 

Dividends
shall be payable to Holders of record of the Series A Preferred Stock as they appear on the stock books of the Corporation on the Dividend
Date.

 

    	 

    	 

    

 

Except
as provided in the following paragraph, if the dividend on the Series A Preferred Stock shall not have been paid or set apart in full
for the Series A Preferred Stock when payable, the aggregate deficiency shall be cumulative and shall be fully paid or set apart for
payment before any dividends shall be paid upon or set apart for, or any other distributions paid made on, or any payments made on account
of the purchase, redemption or retirement of, the Common Stock or any other Junior Security. When dividends are not paid in full upon
the shares or fractions of a share of Series A Preferred Stock and any shares pari passu with the Series A Preferred Stock, all
dividends declared upon this series and any other shares pari passu with the Series A Preferred Stock shall be declared, pro rata,
so that the amount of dividends declared per share or fraction of a share on this Series A Preferred Stock and such other shares pari passu with the Series A Preferred Stock shall in all cases bear to each other the same rates that accrued dividends per share on
the shares of Series A Preferred Stock and such other shares pari passu with the Series A Preferred Stock bear to each other.

 

3.
Voting.

 

a.
Voting Rights. Except as provided in Section 3(b) below or as required by law, Holders of the shares of Series A Preferred
Stock shall not have the right to vote on any matter as to which shareholders are required or permitted to vote. Only in the case of
a vote to be taken pursuant to Section 3(b) below or when required by law, each Holder of the shares of Series A Preferred Stock
shall have the right to the number of votes equal to the number of Conversion Shares then issuable upon conversion of the Series A Preferred
Stock held by such Holder.

 

b.
Limitations on Corporate Actions. Notwithstanding anything to the contrary in Section 3(a) above, as long as any shares
of Series A Preferred Stock are outstanding, the Corporation shall not, without the written consent or affirmative vote of the Holders
of no less than sixty-five percent (65%) of the then-outstanding shares of Series A Preferred Stock, consenting or voting (as the case
may be) as a separate class from the Common Stock, either directly or by amendment, merger, consolidation or otherwise:

 

(i)
amend its certificate of incorporation in any manner that adversely affects the rights of the Holders;

 

(ii)
alter or change adversely the voting or other powers, preferences, rights, privileges, or restrictions of the Series A Preferred Stock
contained herein or alter or amend this Certificate of Designations;

 

(iii)
redeem, purchase or otherwise acquire directly or indirectly any Junior Securities or any shares pari passu with the Series A
Preferred Stock;

 

(iv)
directly or indirectly pay or declare any dividend or make any distribution in respect of, any Junior Securities, or set aside any monies
for the purchase or redemption (through a sinking fund or otherwise) of any Junior Securities or any shares pari passu with the
Series A Preferred Stock;

 

(v)
authorize or create any class of stock ranking as to dividends, redemption or distribution of assets upon a Liquidation (as defined in
Section 4 below) senior to the Series A Preferred Stock; or

 

(vi)
enter into any agreement with respect to any of the foregoing.

 

    	2

    	 

    

 

4.
Liquidation, Dissolution, or Winding-Down.

 

a.
Payments to Holders of Series A Preferred Stock. Upon any liquidation, dissolution or winding-down of the Corporation, whether
voluntary or involuntary (a “Liquidation”), the Holders of the shares of Series A Preferred Stock shall be paid in
cash, before any payment shall be paid to the holders of Common Stock, or any other Junior Securities, an amount for each share of Series
A Preferred Stock held by such Holder equal to 100% of the Stated Value thereof plus 100% of any dividends accrued but unpaid thereon
(such applicable amount payable with respect to all shares of Series A Preferred Stock in the aggregate being referred to as the “Aggregate
Series A Liquidation Preference Payment”). If, upon such liquidation, dissolution or winding-up of the Corporation, whether
voluntary or involuntary, the assets available to be distributed among the Holders of shares of Series A Preferred Stock shall be insufficient
to permit payment to the Holders of Series A Preferred Stock of an aggregate amount equal to the Aggregate Series A Liquidation Preference
Payment, then the Holders of shares of Series A Preferred Stock shall share ratably in any distribution of the assets available for distribution
in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution
if all amounts payable on or with respect to such shares were paid in full.

 

b.
Payments to Holders of Junior Securities. After the payment of all preferential amounts required to be paid to the Holders of
the Series A Preferred Stock and any other class or series of stock of the Corporation ranking on liquidation senior to or on a parity
with the Series A Preferred Stock, the holders of Junior Securities then outstanding shall be entitled to receive the remaining assets
of the Corporation available for distribution to its stockholders as otherwise set forth in the Corporation’s certificate of incorporation.

 

5.
Automatic Conversion. Upon the earlier of (a) the closing of the sale of shares of Common Stock to the public at a price per share
of at least $13.88 (subject to adjustment as provided in Section 6 below) (the “Minimum IPO Price”), in a firm commitment
underwritten public offering pursuant to an effective registration statement under the Securities Act, resulting in gross proceeds (before
underwriters’ discounts, commissions and expenses) to the Company of an amount at least equal to the difference between (i) $25,000,000
and (ii) the gross proceeds (before underwriters’ discounts, commissions and expenses) to the Company of the sale by the Company
of the total number of shares of Series A Preferred Stock that are sold (a “Qualified IPO”), or (b) listing of the
Common Stock on the New York Stock Exchange, NYSE American, Nasdaq Global Select Market, Nasdaq Global Market or Nasdaq Capital Market
(or any successor thereto), all outstanding shares of Series A Preferred Stock shall automatically, and without the payment of additional
consideration by the Holder thereof, and without any notice to the Holder thereof or any further action by any Person, be converted into
such number of fully paid and non-assessable shares of Common Stock as is determined by dividing the Stated Value per share plus accrued
and unpaid dividends thereon by the Conversion Price then in effect.

 

The
“Conversion Price” per share of Common Stock shall be equal to (A) in the case of conversion pursuant to clause 5(a)
above, 90% of the gross public offering price per share of Common Stock (before deducting underwriters’ discount, commissions and
expenses) of the Qualified IPO, or (B) in the case of conversion pursuant to clause 5(b) above, $12.49 (subject to adjustment as provided
in Section 6 below) (the “Listing Conversion Price”).

 

    	3

    	 

    

 

b.
Fractional Shares. No fractional shares of Common Stock shall be issued upon conversion of the Series A Preferred Stock. In lieu
of any fractional shares to which the Holder would otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied
by the fair market value of a share of Common Stock as determined in good faith by the Board of Directors, or round-up to the next whole
number of shares, at the Corporation’s option. Whether or not fractional shares would be issuable upon such conversion shall be
determined on the basis of the total number of shares of Series A Preferred Stock of the Holder that at the time are being converted
into Common Stock and the aggregate number of shares of Common Stock issuable upon such conversion.

 

c.
Mechanics of Conversion.

 

i.
Issuance of Common Stock upon Conversion. Not later than five (5) Trading Days after the Conversion Date (the “Share
Delivery Date”), the Corporation shall issue, or cause to be issued, to each converting Holder the number of shares of Common
Stock being acquired upon the conversion of shares of Series A Preferred Stock. All shares of Series A Preferred Stock which shall have
been converted as herein provided shall no longer be deemed to be outstanding, and all rights with respect to such shares shall immediately
cease and terminate at the Share Delivery Date, except only the right of the Holders thereof to receive shares of Common Stock in exchange
therefor as provided herein, and to receive payment in lieu of any fraction of a share otherwise issuable upon such conversion as provided
herein.

 

ii.
Obligation Absolute; Damages. The Corporation’s obligation to issue and deliver the Conversion Shares upon conversion of
Series A Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by
a Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person
or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach
by such Holder or any other Person of any obligation to the Corporation; provided, however, that such delivery shall not
operate as a waiver by the Corporation of any such action that the Corporation may have against such Holder.

 

e.
Reservation of Shares Issuable upon Conversion. The Corporation covenants, so long as the Shares of Series A Preferred Stock are
outstanding, that it will at all times reserve and keep available out of its authorized and unissued shares of Common Stock for the sole
purpose of issuance upon conversion of the Series A Preferred Stock, free from preemptive rights or any other actual contingent purchase
rights of Persons other than the Holders of the Series A Preferred Stock, not less than such aggregate number of shares of the Common
Stock as shall be issuable upon the conversion of all outstanding shares of Series A Preferred Stock. The Corporation covenants that
all shares of Common Stock that shall be so issuable shall, upon issue in accordance with the terms herein, be duly authorized, validly
issued, fully paid and nonassessable.

 

    	4

    	 

    

 

6.
Certain Adjustments.

 

a.
Subdivision or Combination of Stock. If, at any time while the Series A Preferred Stock is outstanding, the Corporation shall
subdivide (whether by way of stock dividend, stock split or otherwise) its outstanding shares of Common Stock into a greater number of
shares, each of the Minimum IPO Price and the Listing Conversion Price in effect immediately prior to such subdivision shall be proportionately
reduced, and conversely, in case the outstanding shares of Common Stock of the Corporation shall be combined (whether by way of stock
combination, reverse stock split or otherwise) into a smaller number of shares, each of the Minimum IPO Price and the Listing Conversion
Price in effect immediately prior to such combination shall be proportionately increased. Each of the Minimum IPO Price and the Listing
Conversion Price, as so adjusted, shall be readjusted in the same manner upon the happening of any successive event or events described
in this Section 6(a).

 

b.
Dividends in Stock, Property, Reclassification. If, at any time while the Series A Preferred Stock is outstanding, the holders
of Common Stock (or any shares of stock or other securities at the time receivable upon the conversion of the Series A Preferred Stock)
shall have received or become entitled to receive, without payment therefore:

 

(i)
any Common Stock Equivalents, or any rights or options to subscribe for, purchase or otherwise acquire any of the foregoing by way of
dividend or other distribution, or

 

(ii)
additional stock or other securities or property (other than cash in respect of which shall be covered by the terms of Section 3(c) above)
by way of spin-off, split- up, reclassification, combination of shares or similar corporate rearrangement (other than shares of Common
Stock issued as a stock split or adjustments in respect of which shall be covered by the terms of Section 6(a) above),

 

then
and in each such case, each of the Minimum IPO Price and the Listing Conversion Price shall be adjusted proportionately, and the Holder
hereof shall, upon the conversion of the Series A Preferred Stock, be entitled to receive, in addition to the number of shares of Common
Stock receivable thereupon, and without payment of any additional consideration therefor, the amount of stock and other securities and
property that such Holder would hold on the date of such exercise had such Holder been the holder of record of such Common Stock as of
the date on which holders of Common Stock received or became entitled to receive such shares or all other additional stock and other
securities and property. Each of the Minimum IPO Price and the Listing Conversion Price, as so adjusted, shall be readjusted in the same
manner upon the happening of any successive event or events described in this Section 6(b).

 

    	5

    	 

    

 

c.
Reorganization, Reclassification, Consolidation, Merger or Sale. At any time while the Series A Preferred Stock is outstanding,
if any recapitalization, reclassification or reorganization of the capital stock of the Corporation, or any consolidation or merger of
the Corporation with another corporation, or the sale of all or substantially all of its assets or other transaction shall be effected
in such a way that holders of Common Stock shall be entitled to receive stock, securities or other assets or property (an “Organic
Change”), then lawful and adequate provisions shall be made by the Corporation whereby the Holders shall thereafter have the
right to purchase and receive (in lieu of the shares of the Common Stock of the Corporation immediately theretofore purchasable and receivable
upon the conversion of the Series A Preferred Stock) such shares of stock, securities or other assets or property as may be issued or
payable with respect to or in exchange for a number of outstanding shares of such Common Stock equal to the number of shares of such
stock immediately theretofore purchasable and receivable assuming the full conversion of the Series A Preferred Stock. In the event of
any Organic Change, appropriate provision shall be made by the Corporation with respect to the rights and interests of the Holders to
the end that the provisions hereof (including, without limitation, provisions for adjustments of the Minimum IPO Price and the Listing
Conversion Price) shall thereafter be applicable, in relation to any shares of stock, securities or assets thereafter deliverable upon
the conversion thereof. To the extent necessary to effect the foregoing provisions, the successor corporation (if other than the Corporation)
resulting from such consolidation or merger or the corporation purchasing such assets shall assume by written instrument executed and
mailed or delivered to each Holder at the last address of such Holder appearing on the books of the Corporation, the obligation to deliver
to such Holder such shares of stock, securities or assets as, in accordance with the foregoing provisions, such Holder may be entitled
to purchase. If there is an Organic Change, then the Corporation shall cause to be mailed to each Holder at its last address as it shall
appear on the books and records of the Corporation, at least ten (10) calendar days before the effective date of the Organic Change,
a notice stating the date on which such Organic Change is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares for securities, cash, or other property delivered
upon such Organic Change; provided, that the failure to mail such notice or any defect therein or in the mailing thereof shall
not affect the validity of the corporate action required to be specified in such notice. Each Holder is entitled to convert such Holder’s
Series A Preferred Stock during the 10-day period commencing on the date of such notice to the effective date of the event triggering
such notice. In any event, the successor corporation (if other than the Corporation) resulting from such consolidation or merger or the
corporation purchasing such assets shall be deemed to assume such obligation to deliver to such Holder such shares of stock, securities
or assets even in the absence of a written instrument assuming such obligation to the extent such assumption occurs by operation of law.

 

d.
Certificate as to Adjustments. Upon the occurrence of each adjustment or readjustment pursuant to this Section 6, the Corporation
at its expense shall promptly compute such adjustment or readjustment in accordance with the terms hereof and furnish to each Holder
a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment
is based. The Corporation shall promptly furnish or cause to be furnished to such Holder a like certificate setting forth: (i) such adjustments
and readjustments; and (ii) the number of shares and the amount, if any, of other property which at the time would be received upon the
conversion of the Series A Preferred Stock.

 

7.
Optional Redemption. Shares of the Series A Preferred Stock shall be redeemable in cash, in whole or in part, at the option of
the Corporation, by resolution of its Board of Directors, at any time, subject to the Redemption Notice requirements below, at a price
per share equal to one hundred percent (100%) of the Stated Value plus one hundred percent (100%) of the amount of accrued but unpaid
dividends thereon. The Corporation shall provide written notice to all Holders of record of shares of Series A Preferred Stock specifying
the time (the “Redemption Date”) and place of such redemption (the “Redemption Notice”), at their
respective addresses as the same shall appear on the stock books of the Corporation, but no failure on the part of the shareholder to
receive such notice and no defect in the wording of the notice shall affect the validity of the proceedings adopted with respect to the
redemption of any such shares. The Redemption Notice shall be given not less than thirty (30) days prior to the Redemption Date.

 

    	6

    	 

    

 

8.
Status of Series A Preferred Stock Converted or Reacquired. Shares of Series A Preferred Stock converted into Common Stock or
reacquired by the Corporation in any manner, including shares purchased or redeemed, shall (upon compliance with any applicable provisions
of the laws of the State of Delaware) have the status of authorized and unissued shares of the class of Preferred Stock undesignated
as to series, and may be redesignated and reissued as part of any series of the Preferred Stock.

 

9.
Calculations. In the case of a dispute as to the determination of the Conversion Price, or the arithmetic calculation of the number
of shares of Common stock to be issued upon any conversion of Series A Preferred Stock or of the amount of accrued dividends on the Series
A Preferred Stock (a “Disputed Amount”), the Corporation or the Holder (as the case may be) shall submit the disputed
determinations or arithmetic calculations (as the case may be) via facsimile or e-mail (i) within two (2) Trading Days after receipt
of the applicable notice giving rise to such dispute to the Corporation or the Holder (as the case may be), or (ii) if no notice gave
rise to such dispute, at any time after the Holder learned of the circumstances giving rise to such dispute. If the Holder and the Corporation
are unable to agree upon such determination or calculation of the Disputed Amount within three Trading Days of such disputed determination
or arithmetic calculation being submitted, then the Corporation shall within five (5) Business Days, submit in writing (a) the disputed
determination of the Conversion Price to an independent, reputable investment bank selected by the Corporation and approved by the Holder,
or (b) the disputed arithmetic calculation of the number of shares of Common stock to be issued upon conversion or the amount of accrued
dividends to the Corporation’s independent certified public accountant. The Corporation shall cause at its expense the investment
bank or the accountant, as the case may be, to perform the determinations or calculations and notify the Corporation and the Holder of
the results no later than ten (10) Trading Days from the time it receives the disputed determinations or calculations; provided that,
if such disputed determination or arithmetic calculation being submitted by the Holder is determined to be incorrect, then the expense
of the investment bank or the accountant shall be the responsibility of the Holder. Such investment bank’s or accountant’s
determination or calculation, as the case may be, shall be final, binding and conclusive upon the parties thereto.

 

10.
Definitions. As used herein, the following terms shall have the following meanings:

 

	 	a.	“Business
    Day” means any day except Saturday, Sunday, any day which shall be a federal legal holiday in the United States or any
    day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.
	 	 	 
	 	b.	“Common
    Stock” means the Corporation’s common stock, par value $0.0001 per share.

 

    	7

    	 

    

 

	 	c.	“Common
    Stock Equivalents” means any securities of the Corporation which would entitle the holder thereof to acquire at any time
    Common Stock, including without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any
    time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.
	 	 	 
	 	d.	“Conversion
    Date” with respect to any share of Series A Preferred Stock means any day on which such share is to be converted into Common
    Stock pursuant to Section 5.
	 	 	 
	 	e.	“Conversion
    Shares” means, collectively, the shares of Common Stock issuable upon conversion of the shares of Series A Preferred Stock
    in accordance with the terms hereof.
	 	 	 
	 	f.	“Holder”
    means a holder of Series A Preferred Stock.
	 	 	 
	 	g.	“Junior
    Securities” means the Common Stock and all other securities of the Corporation, including Common Stock Equivalents of the
    Corporation, other than those securities which are explicitly senior or pari passu to the Series A Preferred Stock in dividend
    rights or liquidation preference.
	 	 	 
	 	h.	“Person”
    shall mean any individual, partnership, firm, corporation, association, trust, unincorporated organization or other entity, as well
    as any syndicate or group that would be deemed to be a person under Section 13(d)(3) of the Securities Exchange Act of 1934, as amended.
	 	 	 
	 	i.	“Principal
    Market” means the primary national or regional stock exchange on which the Common Stock is listed, or if not so listed,
    OTC Markets, if quoted thereon, is open for the transaction of business
	 	 	 
	 	j.	“Securities
    Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
	 	 	 
	 	k.	“Trading
    Day” means any day on which the Common Stock is traded on the Principal Market.

 

[SIGNATURE
PAGE FOLLOWS.]

 

    	8

    	 

    

 

IN
WITNESS WHEREOF, this Certificate of Designations, Preferences and Rights of Series A Preferred Stock has been executed by a duly authorized
officer of the Corporation on this _____ day of _____, 2018.

 

	 	SHUTTLE
    PHARMACEUTICALS HOLDINGS, INC.
	 	 
	 	By:	 
	 	Name:	Anatoly
    Dritschilo
	 	Title:	Chief
    Executive Officer and President

    

 

    	 

    	 

    

 

EXHIBIT
C

 

Form
of Registration Rights Agreement

 

    	 

    	 

    

 

FINAL

 

FORM
OF 

REGISTRATION RIGHTS AGREEMENT

 

This
Registration Rights Agreement (this “Agreement”) is made and entered into as of _________ ___, 2018, among Shuttle
Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), each of the persons who have executed
omnibus or counterpart signature page(s) hereto (each, a “Subscriber” and, collectively, the
“Subscribers”), and the persons or entities identified on Schedule 1 hereto holding Placement Agent
Warrants (collectively, the “Brokers”). All capitalized terms not otherwise defined herein shall have the meaning
set for in the Subscription Agreement (as defined below) between the Company and each of the Subscribers hereto.

 

RECITALS:

 

WHEREAS,
the Company has offered and sold in compliance with Section 4(a)(2) and/or Rule 506 of Regulation D promulgated under the Securities
Act to accredited investors in a private placement offering (the “Offering”) an aggregate of up to $11,500,000 units
of securities (the “Units”) at a purchase price of $1,000 per Unit (the “Purchase Price), with
each Unit consisting of (i) one share of the Company’s Series A Preferred Stock (as defined below) (the “Offering Shares”)
and (ii) a warrant (the “Offering Warrant”), to be issued upon the earlier of the closing of a Qualified IPO or a
Listing, which Offering Warrants are exercisable for a period of three (3) years from the date of issuance and represent the right to
purchase a number of shares of Common Stock (as defined below) equal to the number of shares into which such shares of Series A Preferred
Stock will be converted, at a per share exercise price equal to the per share price of the Company’s IPO or, if a Qualified IPO
has not yet occurred, at $20.82 per share, as set forth in the Subscription Agreements (the “Subscription Agreements”)
between the Company and each of the Subscribers; and

 

WHEREAS,
each share of Series A Preferred Stock is automatically convertible into shares of the Company’s Common Stock on the terms and
conditions set forth in the Certificate of Designations, Preferences and Rights for the Preferred Stock;

 

WHEREAS,
the Company has agreed to enter into a registration rights agreement with each of the Subscribers to the Offering who purchased Offering
Shares and Offering Warrants, granting such Subscribers certain registration rights with respect to the shares of Common Stock issuable
to such Subscribers upon (i) the conversion of the Offering Shares; and (ii) the exercise of the Offering Warrants; and

 

WHEREAS,
the Company has agreed to enter into a registration rights agreement with each of the Brokers who hold Placement Agent Warrants, granting
such Brokers certain registration rights with respect to the shares of Common Stock issuable to such Brokers upon the exercise of the
Placement Agent Warrants;

 

    	 

    	 

    

 

NOW,
THEREFORE, in consideration of the mutual promises, representations, warranties, covenants, and conditions set forth herein, the
parties mutually agree as follows:

 

1.
Certain Definitions. Capitalized terms used herein without definition have the meanings ascribed to them in the Subscription Agreement.
As used in this Agreement, the following terms shall have the following respective meanings:

 

“Blackout
Period” means, with respect to a registration, a period during which the Company, in the good faith judgment of its board of
directors, determines (because of the existence of, or in anticipation of, any acquisition, financing activity, or other transaction
involving the Company, or the unavailability for reasons beyond the Company’s control of any required financial statements, disclosure
of information which is in its best interest not to publicly disclose, or any other event or condition of similar significance to the
Company) that the registration and distribution of the Registrable Securities to be covered by such registration statement, if any, or
the filing of an amendment to such registration statement in the circumstances described in Section 3(h), would be seriously detrimental
to the Company and its stockholders, in each case commencing on the day the Company notifies the Holders that they are required, because
of the determination described above, to suspend offers and sales of Registrable Securities and ending on the earlier of (1) the date
upon which the material non- public information resulting in the Blackout Period is disclosed to the public or ceases to be material
and (2) such time as the Company notifies the selling Holders that sales pursuant to such Registration Statement or a new or amended
Registration Statement may resume; provided, however, that no Blackout Period shall extend for a period of more than fifteen (15) consecutive
Trading Days (except for a Blackout Period arising from the filing of a post-effective amendment to the Registration Statement to update
the prospectus therein to include the information contained in the Company’s Annual Report on Form 10-K, which Blackout Period
may extend for the amount of time reasonably required to respond to comments of the staff of the Commission (the “Staff”)
on such amendment).

 

“Commission”
means the U. S. Securities and Exchange Commission or any other federal agency at the time administering the Securities Act.

 

“Effective
Date” means the date of the final closing of the Offering.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission promulgated thereunder.

 

“Family
Member” means (a) with respect to any individual, such individual’s spouse, any descendants (whether natural or adopted),
any trust all of the beneficial interests of which are owned by any of such individuals or by any of such individuals together with any
organization described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended, the estate of any such individual, and
any corporation, association, partnership or limited liability company all of the equity interests of which are owned by those above
described individuals, trusts or organizations and (b) with respect to any trust, the owners of the beneficial interests of such trust.

 

    	2

    	 

    

 

“Holder”
means (i) each Subscriber or any of such Subscriber’s respective successors and Permitted Assignees who acquire rights in accordance
with this Agreement with respect to any Registrable Securities directly or indirectly from a Subscriber or from any Permitted Assignee,
and (ii) each Broker or any of such Broker’s respective successors and Permitted Assignees who acquire rights in accordance with
this Agreement with respect to any Registrable Securities directly or indirectly from an Broker or from any Permitted Assignee.

 

“IPO
Registration Statement” means a registration statement filed pursuant to an IPO, as described in Section 3(a) of this Agreement.

 

“Majority
Holders” means, at any time, Holders of a majority of the Registrable Securities then outstanding.

 

“Permitted
Assignee” means (a) with respect to a partnership, its partners or former partners in accordance with their partnership interests,
(b) with respect to a corporation, its stockholders in accordance with their interest in the corporation, (c) with respect to a limited
liability company, its members or former members in accordance with their interest in the limited liability company, (d) with respect
to an individual party, any Family Member of such party, (e) an entity that is controlled by, controls, or is under common control with
a transferor, or (f) a party to this Agreement.

 

“Placement
Agent Warrants” shall have the meaning set forth in the Subscription Agreement.

 

The
terms “register,” “registered,” and “registration” refer to a registration effected
by preparing and filing a registration statement with the Commission in compliance with the Securities Act, and the declaration or ordering
of the effectiveness of such registration statement.

 

“Registrable
Securities” means (a) the Shares but excluding any otherwise Registrable Securities that (i) have been sold or otherwise transferred
other than to a Permitted Assignee, (ii) may be sold under the Securities Act without volume limitations either pursuant to Rule 144
of the Securities Act or otherwise during any ninety (90) day period, or (iii) are at the time subject to an effective registration statement
under the Securities Act.

 

“Registration
Effectiveness Date” means the date that is one hundred twenty (120) calendar days after the date of the initial filing of the
Resale Registration Statement.

 

“Registration
Statement” means an IPO Registration Statement, filed pursuant to Section 3(a), and/or a Resale Registration Statement, filed
pursuant to Section 3(b), if applicable, to register the Registrable Securities.

 

“Resale
Registration Statement” means a resale registration statement prepared pursuant to Section 3(b) of this Agreement.

 

    	3

    	 

    

 

“Rule
144” means Rule 144 promulgated by the Commission under the Securities Act, as such rule may be amended or supplemented from
time to time, or any similar successor rule that may be promulgated by the Commission.

 

“Rule
145” means Rule 145 promulgated by the Commission under the Securities Act, as such rule may be amended or supplemented from
time to time, or any similar successor rule that may be promulgated by the Commission.

 

“Rule
415” means Rule 415 promulgated by the Commission under the Securities Act, as such rule may be amended or supplemented from
time to time, or any similar successor rule that may be promulgated by the Commission.

 

“Securities
Act” means the Securities Act of 1933, as amended, or any similar federal statute promulgated in replacement thereof, and the
rules and regulations of the Commission thereunder, all as the same shall be in effect at the time.

 

“Shares”
means the shares of Common Stock issued or issuable to the Holders upon conversion or exercise of the Offering Shares, Offering Warrants
and Placement Agent Warrants, if any, and any shares of Common Stock issued or issuable at any time on or after the Effective Date and
prior to the second (2nd) anniversary of the SEC Effective Date as a result of any stock split, dividend or other distribution,
recapitalization or similar event with respect to the foregoing.

 

“Trading
Day” means any day on which such national securities exchange, the OTC Markets Group or such other securities market or quotation
system which constitutes the principal securities market for the Common Stock, is open for general trading of securities.

 

2.
Term. This Agreement shall terminate with respect to each Holder on the earlier of: (i) the second (2nd) anniversary
from the date the Resale Registration Statement is declared effective by the Commission; (ii) the date on which all Registrable Securities
held by such Holder are transferred (other than to a Permitted Assignee), (iii) the date on which all Holders may sell all of the Registrable
Securities without restriction pursuant to Rule 144 (including without limitation, volume restrictions) and without the need for current
public information as required by Rule 144(c)(1) or Rule 144(i)(2), if applicable; or (iv) the date this Agreement is otherwise terminated
as provided herein.

 

    	4

    	 

    

 

3.
Registration.

 

(a)
IPO Registration Statement. If, following the date hereof, the Company shall determine to register for sale for cash any of its
Common Stock through an IPO (the “IPO Registration Statement”), for its own account or for the account of others (other
than the Holders), other than (i) a registration relating solely to employee benefit plans or securities issued or issuable to employees,
consultants (to the extent the securities owned or to be owned by such consultants could be registered on Form S-8 (or its then equivalent
form) or any of their Family Members (including a registration on Form S-8 (or its then equivalent form)), (ii) a registration relating
solely to a Securities Act Rule 145 transaction or a registration on Form S-4 (or its then equivalent form) in connection with a merger,
acquisition, divestiture, reorganization or similar event, or (iii) a transaction relating solely to the sale of debt or convertible
debt instruments, then the Company shall promptly give to each Holder written notice thereof (the “Registration Rights Notice”)
that the Company intends to include all of the Registerable Securities in the IPO Registration Statement. Nonetheless, the Company may,
without the consent of such Holders, remove some or all of the Registrable Securities from the IPO Registration Statement if the managing
underwriter or the Company determines that marketing factors require a limitation on the number of shares of Common Stock or the amount
of other securities to be included in the IPO Registration Statement or if the staff of the Commission (the “Commission Staff”)
otherwise requires such removal. The Company shall then use its commercially reasonable efforts to cause such IPO Registration Statement
to be declared effective, and the IPO to be closed, within twelve (12) months following the Effective Date;

 

(b)
Resale Registration Statement. If an IPO Registration Statement has not been declared effective with respect to all of the Registrable
Shares by the first anniversary of the Effective Date, then, within 60 days following such anniversary date, the Company will prepare
and file with the Commission a Resale Registration Statement with respect to the Registrable Shares not included in an effective IPO
Registration Statement. The Company will then use its commercially reasonable efforts to cause such Resale Registration Statement to
be declared effective (the “Registration Effectiveness Date”) within 120 days after the initial filing of the Resale
Registration Statement. Notwithstanding the foregoing, in the event that the Commission Staff should limit the number of Registrable
Securities that may be sold pursuant to the Resale Registration Statement, the Company may remove from the Resale Registration Statement
such number of Registrable Securities as specified by the Staff first from the shares of Common Stock issued or issuable upon
exercise of the Placement Agent Warrants, if any, on a pro rata basis among the Holders thereof, and second from the other Registrable
Securities, on a pro rata basis among the Holders thereof (such Registrable Securities, the “Reduction Securities”).
In such event, the Company shall give the Holders prompt notice of the number of Registrable Securities excluded therefrom. The Company
shall use its commercially reasonable efforts at the first opportunity permitted by the Commission to register for resale the Reduction
Securities (on a pro rata basis among the Holders of such Reduction Securities, as needed) using one or more registration statement.

 

    	5

    	 

    

 

(c)
Effectiveness Period. The Company shall use its commercially reasonable efforts to keep such Registration Statement(s) effective
for a period of two (2) years commencing on the SEC Effective Date or for such shorter period ending on the earlier to occur of (i) the
date on which all Registrable Securities have been transferred other than to a Permitted Assignee and (ii) the date as of which all of
the Holders may sell all of the Registrable Securities without restriction pursuant to Rule 144 (including, without limitation, volume
restrictions) and without the need for current public information required by Rule 144(c)(1) or Rule 144(i)(2), if applicable (the “Effectiveness
Period”); provided, however, that the Company shall not be obligated to effect any such registration, qualification or compliance
pursuant to this Section, or keep such registration effective pursuant to the terms hereunder, in any particular jurisdiction in which
the Company would be required to qualify to do business as a foreign corporation or as a dealer in securities under the securities laws
of such jurisdiction or to execute a general consent to service of process in effecting such registration, qualification or compliance,
in each case, where it has not already done so. Notwithstanding the foregoing, the Company shall be entitled to suspend the effectiveness
of such Registration Statement at any time prior to the expiration of the Effectiveness Period for the reasons and time periods as may
be required during a Blackout Period.

 

4.
Registration Procedures. The Company will keep each Holder reasonably advised as to the filing and effectiveness of the IPO Registration
Statement and the Resale Registration Statement, as applicable. At its expense, solely with respect to such Registration Statement, the
Company will:

 

(a)
prepare and file with the Commission the IPO Registration Statement, in accordance with Section (a) hereof covering the resale of the
Registrable Securities, and, if so filed, use its commercially reasonable efforts to cause such IPO Registration Statement to become
effective;

 

(b)
prepare and file the Resale Registration Statement, if necessary, in accordance with Section 3(b), and use its commercially reasonable
efforts to cause such Resale Registration Statement to be declared effective no later than 120 days after the initial filing of the Resale
Registration Statement and to remain effective for the Effectiveness Period;

 

(c)
not name any Holder in the Registration Statement as an underwriter without that Holder’s prior written consent;

 

(d)
if any of the Registration Statements are subject to review by the Commission, promptly respond to all comments and diligently pursue
resolution of any comments to the satisfaction of the Commission;

 

(e)
prepare and file with the Commission such amendments and supplements to such Registration Statement as may be necessary to keep such
Registration Statement effective during the Effectiveness Period;

 

(f)
furnish, without charge, to each Holder of Registrable Securities covered by such Registration Statement (i) a reasonable number of copies
of such Registration Statement (including any exhibits thereto other than exhibits incorporated by reference), and each amendment and
supplement thereto as such Holder may reasonably request, (ii) such number of copies of the prospectus included in such Registration
Statement (including each preliminary prospectus and any other prospectus filed under Rule 424 of the Securities Act) as such Holders
may reasonably request, in conformity with the requirements of the Securities Act, and (iii) such other documents as such Holder may
reasonably require to consummate the disposition of the Registrable Securities owned by such Holder, but only during the Effectiveness
Period; provided that the Company shall have no obligation to furnish any document pursuant to this clause that is available on the Commission’s
EDGAR system;

 

    	6

    	 

    

 

(g)
use its commercially reasonable efforts to register or qualify such registration under such other applicable securities laws of such
jurisdictions within the United States as any Holder of Registrable Securities covered by the applicable Registration Statement reasonably
requests and as may be necessary for the marketability of the Registrable Securities (such request to be made by the time the applicable
Registration Statement is deemed effective by the Commission) and do any and all other acts and things necessary to enable such Holder
to consummate the disposition in such jurisdictions of the Registrable Securities owned by such Holder; provided, that the Company
shall not be required to (i) qualify generally to do business in any jurisdiction where it would not otherwise be required to qualify
but for this paragraph, (ii) subject itself to taxation in any such jurisdiction, or (iii) consent to general service of process in any
such jurisdiction;

 

(h)
as promptly as practicable after becoming aware of an event the disposition of which requires the delivery of a prospectus relating thereto
under the Securities Act, notify each Holder of Registrable Securities of the happening of any event, which comes to the Company’s
attention, that will after the occurrence of such event cause the prospectus included in such Registration Statement, if not amended
or supplemented, to contain an untrue statement of a material fact or an omission to state a material fact required to be stated therein
or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading and the Company
shall promptly thereafter prepare and furnish to such Holder a supplement or amendment to such prospectus (or prepare and file appropriate
reports under the Exchange Act) so that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus shall
not contain an untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make
the statements therein, in the light of the circumstances under which they were made, not misleading, unless suspension of the use of
such prospectus otherwise is authorized herein or in the event of a Blackout Period, in which case no supplement or amendment need be
furnished (or Exchange Act filing made) until the termination of such suspension or Blackout Period; provided that any and all information
provided to the Holder pursuant to such notification shall remain confidential to each Holder until such information otherwise becomes
public, unless disclosure by a Holder is required by law;

 

(i)
comply, and continue to comply during the Effectiveness Period, in all material respects with the Securities Act and the Exchange Act
and with all applicable rules and regulations of the Commission with respect to the disposition of all securities covered by such Registration
Statement;

 

    	7

    	 

    

 

(j)
as promptly as practicable after becoming aware of such event, notify each Holder of Registrable Securities being offered or sold pursuant
to the applicable Registration Statement of the issuance by the Commission of any stop order or other suspension of effectiveness of
the Registration Statement;

 

(k)
use its commercially reasonable efforts to cause all the Registrable Securities covered by the Registration Statement to be listed on
a Qualified Exchange;

 

(l)
provide a transfer agent and registrar, which may be a single entity, for the shares of Common Stock at all times;

 

(m)
cooperate with the Holders of Registrable Securities being offered pursuant to the IPO Registration Statement or the Resale Registration
Statement, as applicable, to issue and deliver, or cause its transfer agent to issue and deliver, certificates representing Registrable
Securities to be offered pursuant to the applicable Registration Statement within a reasonable time after the delivery of certificates
representing the Registrable Securities to the transfer agent or the Company, as applicable, and enable such certificates to be in such
denominations or amounts as the Holders may reasonably request and registered in such names as the Holders may request;

 

(n)
during the Effectiveness Period, refrain from bidding for or purchasing any Common Stock or any right to purchase Common Stock or attempting
to induce any person to purchase any such security or right if such bid, purchase or attempt would in any way limit the right of the
Holders to sell Registrable Securities by reason of the limitations set forth in Regulation M of the Exchange Act; and

 

(o)
take all other commercially reasonable actions necessary to expedite and facilitate the disposition by the Holders of the Registrable
Securities pursuant to the applicable Registration Statement during the term of this Agreement; provided, however, the
Company is not obligated under this clause (o) to expend any of the Company’s funds, other than the costs and expenses specifically
required under Section 6 of this Agreement.

 

5.
Obligations of the Holders.

 

(a)
Each Holder agrees that, upon receipt of any notice from the Company of the happening of any event of the kind described in Section 3(h)
hereof or of the commencement of a Blackout Period, such Holder shall discontinue the disposition of Registrable Securities included
in the Registration Statement until such Holder’s receipt of the copies of the supplemented or amended prospectus contemplated
by Section 3(h) hereof or notice of the end of the Blackout Period, and, if so directed by the Company, such Holder shall deliver to
the Company (at the Company’s expense) all copies (including, without limitation, any and all drafts), other than permanent file
copies, then in such Holder’s possession, of the prospectus covering such Registrable Securities current at the time of receipt
of such notice.

 

    	8

    	 

    

 

(b)
The Holders of the Registrable Securities shall provide such information as may reasonably be requested by the Company, or the managing
underwriter, if any, in connection with the preparation of any registration statement, including amendments and supplements thereto,
in order to effect the registration of any Registrable Securities under the Securities Act pursuant to Section 3(a) and/or 3(b) of this
Agreement and in connection with the Company’s obligation to comply with federal and applicable state securities laws, including
a completed questionnaire in the form attached to this Agreement as Annex A (a “Selling Securityholder Questionnaire”)
or any update thereto not later than three (3) Business Days following a request therefor from the Company.

 

(c)
Each Holder, by its acceptance of the Registrable Securities, agrees to cooperate with the Company as reasonably requested by the Company
in connection with the preparation and filing of any Registration Statement hereunder, unless such Holder has notified the Company in
writing of its election to exclude all of its Registrable Securities from such Registration Statement.

 

6.
Registration Expenses. The Company shall pay all expenses in connection with any registration obligation provided herein, including,
without limitation, all registration, filing, stock exchange fees, printing expenses, all fees and expenses of complying with applicable
securities laws, and the fees and disbursements of counsel for the Company (but not for the Holders)and of the Company’s independent
accountants; provided, that, in any underwritten registration, the Company shall have no obligation to pay any underwriting discounts,
selling commissions or transfer taxes attributable to the Registrable Securities being sold by the Holders thereof, which underwriting
discounts, selling commissions and transfer taxes shall be borne by such Holders. Additionally, in an underwritten offering, all selling
stockholders and the Company shall bear the expenses of the underwriter pro rata in proportion to the respective amount of shares each
is selling in such offering. Except as provided in this Section 6 and Section 8 of this Agreement, the Company shall not be responsible
for the expenses of any attorney or other advisor employed by a Holder.

 

7.
Assignment of Rights. No Holder may assign its rights under this Agreement to any party without the prior written consent of the
Company; provided, however, that any Holder may assign its rights under this Agreement without such consent to a Permitted
Assignee as long as (a) such transfer or assignment is effected in accordance with applicable securities laws; (b) such transferee or
assignee agrees in writing to become bound by and subject to the terms of this Agreement; and (c) such Holder notifies the Company in
writing of such transfer or assignment, stating the name and address of the transferee or assignee and identifying the Registrable Securities
with respect to which such rights are being transferred or assigned. The Company may assign this Agreement or any rights or obligations
hereunder without the prior written consent of any other party hereto.

 

    	9

    	 

    

 

8.
Indemnification.

 

(a)
In the event of the offer and sale of Registrable Securities under the Securities Act, the Company shall, and hereby does, indemnify
and hold harmless, to the fullest extent permitted by law, each Holder, its directors, officers, partners, and each other person, if
any, who controls or is under common control with such Holder within the meaning of Section 15 of the Securities Act, against any losses,
claims, damages or liabilities, joint or several, and expenses to which the Holder or any such director, officer, partner or controlling
person may become subject under the Securities Act or otherwise, insofar as such losses, claims, damages, liabilities or expenses (or
actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon any untrue statement of any
material fact contained in any registration statement prepared and filed by the Company under which Registrable Securities were registered
under the Securities Act, any preliminary prospectus, final prospectus or summary prospectus contained therein, or any amendment or supplement
thereto, or any omission to state therein a material fact required to be stated or necessary to make the statements therein, in light
of the circumstances in which they were made, not misleading, and the Company shall reimburse the Holder, and each such director, officer,
partner and controlling person for any legal or any other expenses reasonably incurred by them in connection with investigating, defending
or settling any such loss, claim, damage, liability, action or proceeding; provided, however, that the indemnity obligation
of the Company under this Section 8(a) to any Holder shall in no event exceed the net proceeds from the Offering received by the Company
from such Holder (or Holder’s predecessor-in-interest); and provided further, that the Company shall not be liable in any
such case (i) to the extent that any such loss, claim, damage, or liability (or action or proceeding in respect thereof) or expense arises
out of or is based upon (x) an untrue statement in or omission from such registration statement, any such preliminary prospectus, final
prospectus, summary prospectus, amendment or supplement in reliance upon and in conformity with written information furnished by a Holder
or its representative to the Company for use in the preparation thereof or (y) the failure of a Holder to comply with the covenants and
agreements contained in Section 5 hereof respecting the sale of Registrable Securities; or (ii) if the person asserting any such loss,
claim, damage or liability (or action or proceeding in respect thereof) who purchased the Registrable Securities that are the subject
thereof did not receive a copy of an amended preliminary or final prospectus or the final prospectus (or the final prospectus as amended
or supplemented) at or prior to the written confirmation of the sale of such Registrable Securities to such person because of the failure
of such Holder to so provide such amended preliminary or final prospectus and the untrue statement or omission of a material fact made
in such preliminary or final prospectus was corrected in the amended preliminary or final prospectus (or the final prospectus as amended
or supplemented). Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Holders,
or any such director, officer, partner or controlling person and shall survive the transfer of such shares by the Holder.

 

    	10

    	 

    

 

(b)
As a condition to including Registrable Securities in any registration statement filed pursuant to this Agreement, each Holder agrees
to be bound by the terms of this Section 8 and to indemnify and hold harmless, to the fullest extent permitted by law, the Company, each
of its directors, officers, partners, legal counsel and accountants and each underwriter, if any, and each other person, if any, who
controls the Company within the meaning of Section 15 of the Securities Act, against any losses, claims, damages or liabilities, joint
or several, to which the Company or any such director or officer or controlling person may become subject under the Securities Act or
otherwise, insofar as such losses, claims, damages or liabilities (or actions or proceedings, whether commenced or threatened, in respect
thereof) arise out of or are based upon any untrue statement of a material fact or any omission of a material fact required to be stated
in any registration statement, any preliminary prospectus, final prospectus, summary prospectus, amendment or supplement thereto or necessary
to make the statements therein, in light of the circumstances in which they were made, not misleading, to the extent that such untrue
statement or omission is included or omitted in reliance upon and in conformity with written information furnished by the Holder or its
representative to the Company for use in the preparation thereof, and such Holder shall reimburse the Company, and such Holders, directors,
officers, partners, legal counsel and accountants, persons, underwriters, or control persons, each such director, officer, and controlling
person for any legal or other expenses reasonably incurred by them in connection with investigating, defending, or settling any such
loss, claim, damage, liability, action, or proceeding; provided, however, that the indemnity obligation of a Holder under
this Section 8(b) shall in no event exceed the amount of the net proceeds received by such Holder as a result of the sale of such Holder’s
Registrable Securities pursuant to such registration statement, except in the case of fraud or willful misconduct. Such indemnity shall
remain in full force and effect, regardless of any investigation made by or on behalf of the Company or any such director, officer or
controlling person and shall survive the transfer by any Holder of such shares.

 

(c)
Promptly after receipt by an indemnified party of notice of the commencement of any action or proceeding involving a claim referred to
in this Section 8 (including any governmental action), such indemnified party shall, if a claim in respect thereof is to be made against
an indemnifying party, give written notice to the indemnifying party of the commencement of such action; provided, that the failure
of any indemnified party to give notice as provided herein shall not relieve the indemnifying party of its obligations under this Section,
except to the extent that the indemnifying party is actually prejudiced by such failure to give notice. In case any such action is brought
against an indemnified party, unless in the reasonable judgment of counsel to such indemnified party a conflict of interest between such
indemnified and indemnifying parties may exist or the indemnified party may have defenses not available to the indemnifying party in
respect of such claim, the indemnifying party shall be entitled to participate in and to assume the defense thereof, with counsel reasonably
satisfactory to such indemnified party and, after notice from the indemnifying party to such indemnified party of its election so to
assume the defense thereof, the indemnifying party shall not be liable to such indemnified party for any legal or other expenses subsequently
incurred by the latter in connection with the defense thereof, unless in such indemnified party’s reasonable judgment a conflict
of interest between such indemnified and indemnifying parties arises in respect of such claim after the assumption of the defenses thereof
or the indemnifying party fails to defend such claim in a diligent manner, other than reasonable costs of investigation. Neither an indemnified
nor an indemnifying party shall be liable for any settlement of any action or proceeding effected without its consent. No indemnifying
party shall, without the consent of the indemnified party, consent to entry of any judgment or enter into any settlement, which does
not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all
liability in respect of such claim or litigation. Notwithstanding anything to the contrary set forth herein, and without limiting any
of the rights set forth above, in any event any party shall have the right to retain, at its own expense, counsel with respect to the
defense of a claim. Each indemnified party shall furnish such information regarding itself or the claim in question as an indemnifying
party may reasonably request in writing and as shall be reasonably required in connection with defense of such claim and litigation resulting
therefrom.

 

    	11

    	 

    

 

(d)
If an indemnifying party does not or is not permitted to assume the defense of an action pursuant to Section 8(c) or in the case of the
expense reimbursement obligation set forth in Sections 8(a) and 8(b), the indemnification required by Sections 8(a) and 8(b) shall be
made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or
expenses, losses, damages, or liabilities are incurred.

 

(e)
If the indemnification provided for in Section 8(a) or 8(b) is held by a court of competent jurisdiction to be unavailable to an indemnified
party with respect to any loss, liability, claim, damage or expense referred to herein, the indemnifying party, in lieu of indemnifying
such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss,
liability, claim, damage or expense (i) in such proportion as is appropriate to reflect the proportionate relative fault of the indemnifying
party on the one hand and the indemnified party on the other (determined by reference to, among other things, whether the untrue or alleged
untrue statement of a material fact or omission relates to information supplied by the indemnifying party or the indemnified party and
the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such untrue statement or omission),
or (ii) if the allocation provided by clause (i) above is not permitted by applicable law or provides a lesser sum to the indemnified
party than the amount herein provided, then in such proportion as is appropriate to reflect not only the proportionate relative fault
of the indemnifying party and the indemnified party, but also the relative benefits received by the indemnifying party on the one hand
and the indemnified party on the other, as well as any other relevant equitable considerations. No indemnified party guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any indemnifying
party who was not guilty of such fraudulent misrepresentation.

 

(f)
Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement
entered into in connection with an underwritten public offering are in conflict with the foregoing provisions, the provisions in the
underwriting agreement shall control.

 

    	12

    	 

    

 

(g)
Other Indemnification. Indemnification similar to that specified in this Section (with appropriate modifications) shall be given
by the Company and each Holder of Registrable Securities with respect to any required registration or other qualification of securities
under any federal or state law or regulation or governmental authority other than the Securities Act.

 

9.
Rule 144. For a period of at least two (2) years following the Effective Date, the Company will use its commercially reasonable
efforts to timely file all reports required to be filed by the Company after the date hereof under the Exchange Act and the rules and
regulations adopted by the Commission thereunder, and if the Company is not required to file reports pursuant to such sections, it will
prepare and furnish to the Holders and make publicly available in accordance with Rule 144(c) such information as is required for the
Holders to sell shares of Common Stock under Rule 144.

 

10.
Independent Nature of Each Holder’s Obligations and Rights. The obligations of each Holder under this Agreement are several
and not joint with the obligations of any other Holder, and each Holder shall not be responsible in any way for the performance of the
obligations of any other Holder under this Agreement. Nothing contained herein and no action taken by any Holder pursuant hereto, shall
be deemed to constitute such Holders as a partnership, an association, a joint venture, or any other kind of entity, or create a presumption
that the Holders are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by
this Agreement. Each Holder shall be entitled to independently protect and enforce its rights, including without limitation the rights
arising out of this Agreement, and it shall not be necessary for any other Holder to be joined as an additional party in any proceeding
for such purpose.

 

11.
Miscellaneous.

 

(a)
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the United States of America and
the State of New York, both substantive and remedial, without regard to New York conflicts of law principles. Any judicial proceeding
brought against any of the parties to this Agreement or any dispute arising out of this Agreement or any matter related hereto shall
be brought in the courts of the State of New York, New York County, or in the United States District Court for the Southern District
of New York and, by its execution and delivery of this Agreement, each party to this Agreement accepts the jurisdiction of such courts.
The foregoing consent to jurisdiction shall not be deemed to confer rights on any person other than the parties to this Agreement.

 

(b)
Remedies. In the event of a breach by the Company or by a Holder of any of their respective obligations under this Agreement,
each Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement,
including recovery of damages, shall be entitled to specific performance of its rights under this Agreement.

 

    	13

    	 

    

 

(c)
Successors and Assigns. Except as otherwise provided herein, the provisions hereof shall inure to the benefit of, and be binding
upon, the successors, Permitted Assignees, executors and administrators of the parties hereto.

 

(d)
No Inconsistent Agreements. The Company has not entered, as of the date hereof, and shall not enter, on or after the date of this
Agreement, into any agreement with respect to its securities that would have the effect of impairing the rights granted to the Holders
in this Agreement or otherwise conflicts with the provisions hereof. Notwithstanding anything to the contrary contained herewith, except
as specifically provided in this Agreement, any action by the Company which could have the effect of diminishing the value of any Registrable
Securities, including, without limitation, the issuance of additional stock or other securities, the granting of registration rights
to others, and actions in connection with the operation of the business of the Company, shall not by itself, absent bad faith, be deemed
an impairment of the rights granted to the Holders in this Agreement.

 

(e)
Entire Agreement. This Agreement and the documents, instruments and other agreements specifically referred to herein or delivered
pursuant hereto constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof.

 

(f)
Notices, etc. All notices, consents, waivers, and other communications which are required or permitted under this Agreement shall
be in writing and will be deemed given to a party (a) on the date of delivery, if delivered to the appropriate address by hand or by
nationally recognized overnight courier service (costs prepaid); (b) the date of transmission if sent by facsimile or e-mail with confirmation
of transmission by the transmitting equipment if such notice or communication is delivered prior to 5:00 P.M., New York City time, on
a Trading Day, or the next Trading Day after the date of transmission, if such notice or communication is delivered on a day that is
not a Trading Day or later than 5:00 P.M., New York City time, on any Trading Day; (c) the date received or rejected by the addressee,
if sent by certified mail, return receipt requested; or (d) seven days after the placement of the notice into the mails (first class
postage prepaid), to the party at the address, facsimile number, or e-mail address furnished by the such party,

 

if
to the Company, to:

 

Shuttle
Pharmaceuticals Holdings, Inc.

One
Research Court, Suite 450

Rockville, MD 20850

Attention:
Anatoly Dritschilo, M.D.

E-mail
Address: anatoly.dritschilo@shuttlepharma.org

 

with
copy to:

 

CKR
Law LLP

1330
Avenue of the Americas, 14th Floor

New York, NY 10019

Attention:
Megan J. Penick

Facsimile:
+1-212-259-8200

E-mail
Address: mpenick@ckrlaw.com

 

    	14

    	 

    

 

if
to a Subscriber, to:

 

the
address set forth on such Subscriber’s Omnibus Signature Page hereto; or

 

if to a Broker, to:

 

such
Broker at the address set forth on the Broker’s signature page hereto;

 

or
at such other address as any party shall have furnished to the other parties in writing in accordance with this Section 11(f).

 

(g)
Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any Holder, upon any breach or default
of the Company under this Agreement, shall impair any such right, power or remedy of such Holder nor shall it be construed to be a waiver
of any such breach or default, or an acquiescence therein, or of any similar breach or default thereunder occurring; nor shall any waiver
of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit,
consent or approval of any kind or character on the part of any Holder of any breach or default under this Agreement, or any waiver on
the part of any Holder of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent
specifically set forth in such writing. All remedies, either under this Agreement, or by law or otherwise afforded to any holder, shall
be cumulative and not alternative.

 

(h)
Counterparts. This Agreement may be executed in any number of counterparts, and with respect to any Subscriber, by execution of
an Omnibus Signature Page to this Agreement and the Subscription Agreement, each of which shall be enforceable against the parties actually
executing such counterparts, and all of which together shall constitute one instrument. In the event that any signature is delivered
by facsimile transmission or by an e- mail, which contains a portable document format (.pdf) file of an executed signature page, such
signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the
same force and effect as if such facsimile or e-mail of a .pdf signature page were an original thereof.

 

(i)
Severability. In the case any provision of this Agreement shall be invalid, illegal or unenforceable, the validity, legality and
enforceability of the remaining provisions shall not in any way be affected or impaired thereby.

 

(j)
Amendments. Except as otherwise provided herein, the provisions of this Agreement may be amended at any time and from time to
time, and particular provisions of this Agreement may be waived, with and only with an agreement or consent in writing signed by the
Company and the Majority Holders. The Holders acknowledge that by the operation of this Section, the Majority Holders may have the right
and power to diminish or eliminate all rights of the other Holders under this Agreement.

 

[Company
Signature Page Follows]

 

    	15

    	 

    

 

This
Registration Rights Agreement is hereby executed as of the date first above written.

 

	 	

The
Company:

	 	 
	 	SHUTTLE
    PHARMACEUTICALS HOLDINGS, INC.
	 	 	                      
	 	By:	 
	 	Name:	 
	 	Title:	 

 

Subscribers

 

See
Omnibus Signature Pages to the Subscription Agreement

 

	Broker (Individual):	 	Broker (Entity):
	 	 	 
	 	 	 
	Print
    Name	 	Print Name of Entity
	 	 	 	 
	 	 	By:
    	      
	Signature	 	Name: 	 
	 	 	Title:	 

 

	All
    Brokers: Address	 
	 	 
	 	 
	 	 
	 	 

 

    	 

    	 

    

 

Schedule
1

 

Brokers

 

    	 

    	 

    

 

Annex
A

 

Shuttle
Pharmaceuticals Holdings, Inc.

 

Selling
Securityholder Notice and Questionnaire

 

The
undersigned beneficial owner of Registrable Securities of Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the
“Company”), understands that the Company has filed or intends to file with the U.S. Securities and Exchange Commission
a registration statement (the “Registration Statement”) under Rule 415 of the Securities Act of 1933, as amended,
for the registration and resale of the Registrable Securities in accordance with the terms of the Registration Rights Agreement (the
“Registration Rights Agreement”) to which this document is annexed. A copy of the Registration Rights Agreement is
available from the Company upon request at the address set forth below. All capitalized terms not otherwise defined herein shall have
the meanings ascribed thereto in the Registration Rights Agreement.

 

Certain
legal consequences arise from being named as a selling security holder in the Registration Statement and the related prospectus. Accordingly,
holders and beneficial owners of Registrable Securities are advised to consult their own securities law counsel regarding the consequences
of being named or not being named as a selling security holder in the Registration Statement and the related prospectus.

 

NOTICE

 

The
undersigned beneficial owner (the “Selling Securityholder”) of Registrable Securities hereby elects to include the
Registrable Securities owned by it in the Registration Statement.

 

The
undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate:

 

QUESTIONNAIRE

 

1.
Name:

 

	 	(a)	Full
    Legal Name of Selling Securityholder
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	(b)	Full
    Legal Name of Registered Holder (holder of record) (if not the same as (a) above) through which Registrable Securities are held:
	 	 	 
	 	 	 
	 	 	 

 

    	 

    	 

    

 

	 	(c)	If
    you are not a natural person, full Legal Name of Natural Control Person (which means a natural person who directly or indirectly
    alone or with others has power to vote or dispose of the securities covered by this Questionnaire):
	 	 	 
	 	 	 
	 	 	 

 

2.
Address for Notices to Selling Securityholder:

 

 

	 
	Telephone:
    ___________________Fax:  _______________________________________________________________
	Email:
     __________________________________________________________________________________________
	Contact
    Person:  __________________________________________________________________________________

 

3.
Broker-Dealer Status:

 

	 	(a)	Are
    you a broker-dealer?

 

Yes
☐                  No ☐

 

	 	(b)	If
    “yes” to Section 3(a), did you receive your Registrable Securities as compensation for investment banking services to
    the Company?

 

Yes
☐                 No ☐

 

	 	Note:	If
    “no” to Section 3(b), the Commission’s staff has indicated that you should be identified as an underwriter in the
    Registration Statement.

 

	 	(c)	Are
    you an affiliate of a broker-dealer?

 

Yes
☐               No ☐

 

	 	(d)	If
    you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable Securities in the ordinary course of business,
    and at the time of the purchase of the Registrable Securities to be resold, you had no agreements or understandings, directly or
    indirectly, with any person to distribute the Registrable Securities?

 

Yes
☐              No ☐

 

	 	Note:	If
    “no” to Section 3(d), the Commission’s staff has indicated that you should be identified as an underwriter in the
    Registration Statement.

 

    	2

    	 

    

 

4.
Beneficial Ownership of Securities of the Company Owned by the Selling Securityholder:

 

Except
as set forth below in this Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company.

 

(a)
Please list the type (common stock, warrants, etc.) and amount of all securities of the Company (including any Registrable Securities)
beneficially owned1 by the Selling Securityholder:

 

 _________________________________________________________________________________

 _________________________________________________________________________________

 

5.
Relationships with the Company:

 

Except
as set forth below, neither you nor (if you are a natural person) any member of your immediate family, nor (if you are not a natural
person) any of your affiliates2, officers, directors or principal equity holders (owners of 5% of more of the equity securities
of the undersigned) has held any position or office or has had any other material relationship with the Company (or its predecessors
or affiliates) during the past three years.

 

State
any exceptions here:

 

____________________________________________________________

 ____________________________________________________________

 

6.
Method of Distribution:

 

Describe
below Holder’s intended method of distribution.

 

_______________________________________________________________________________________ 

 

 

1 Beneficially
Owned: A “beneficial owner” of a security includes any person who, directly or indirectly, through any contract,
arrangement, understanding, relationship or otherwise has or shares (i) voting power, including the power to direct
the voting of such security, or (ii) investment power, including the power to dispose of, or direct the
disposition of, such security. In addition, a person is deemed to have “beneficial ownership” of a security of which
such person has the right to acquire beneficial ownership at any time within 60 days, including, but not limited to, any
right to acquire such security: (i) through the exercise of any option, warrant or right, (ii) through the conversion of any
security or (iii) pursuant to the power to revoke, or the automatic termination of, a trust, discretionary account or similar
arrangement.

 

It
is possible that a security may have more than one “beneficial owner,” such as a trust, with two co-trustees sharing voting
power, and the settlor or another third party having investment power, in which case each of the three would be the “beneficial
owner” of the securities in the trust. The power to vote or direct the voting, or to invest or dispose of, or direct the investment
or disposition of, a security may be indirect and arise from legal, economic, contractual or other rights, and the determination of beneficial
ownership depends upon who ultimately possesses or shares the power to direct the voting or the disposition of the security.

 

The
final determination of the existence of beneficial ownership depends upon the facts of each case. You may, if you believe the facts warrant
it, disclaim beneficial ownership of securities that might otherwise be considered “beneficially owned” by you.

 

2
Affiliate: An “affiliate” is a company or person that directly, or indirectly through one or more intermediaries,
controls you, or is controlled by you, or is under common control with you.

 ________________________________________________________________________________________

________________________________________________________________________________________

 

The
undersigned agrees to promptly notify the Company of any inaccuracies or changes in the information provided herein that may occur subsequent
to the date hereof at any time while the Registration Statement remains effective.

 

By
signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through 6 and
the inclusion of such information in the Registration Statement and the related prospectus and any amendments or supplements thereto.
The undersigned understands that such information will be relied upon by the Company in connection with the preparation or amendment
of the Registration Statement and the related prospectus and any amendments or supplements thereto.

 

    	3

    	 

    

 

IN
WITNESS WHEREOF the undersigned, by authority duly given, has caused this Selling Securityholder Notice and Questionnaire to be executed
and delivered either in person or by its duly authorized agent.

 

	BENEFICIAL
    OWNER (individual)	 	BENEFICIAL
    OWNER (entity)
	 	 	 
	 	 	 
	Signature	 	Name
    of Entity
	 	 	 
	 	 	 
	Print
    Name	 	Signature
	 	 	 
	 	 	 
		 	Print
    Name: _____________________________________
	Signature
    (if Joint Tenants or Tenants in Common)	 	 
	 	 	Title:___________________________________________

 

PLEASE
E-MAIL OR FAX A COPY OF THE COMPLETED AND EXECUTED SELLING SECURITYHOLDER NOTICE AND QUESTIONNAIRE, AND RETURN THE ORIGINAL BY OVERNIGHT
MAIL, TO:

 

CKR
Law LLP

1330
Avenue of the Americas, 14th Floor

New York, NY 10019

Attention:
Eleanor Osmanoff

Facsimile: (212) 259-8200

E-mail
Address: eosmanoff@ckrlaw.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]